$elv 2021 Q4 10-K

Concept	2021 Q4	2021 Q3	2021
Revenue	$36.58B	$35.82B	$138.6B
YoY Change	14.95%	14.97%	13.76%
Cost Of Revenue		$2.898B	$10.90B
YoY Change		30.42%	21.69%
Gross Profit		$32.92B	$127.7B
YoY Change		13.78%	13.13%
Gross Profit Margin		91.91%	92.14%
Selling, General & Admin	$3.811B	$3.946B	$15.91B
YoY Change	-10.79%	-25.62%	-8.8%
% of Gross Profit		11.99%	12.46%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$360.0M	$351.0M	$136.0M
YoY Change	24.14%	13.96%	-22.73%
% of Gross Profit		1.07%	0.11%
Operating Expenses	$34.55B	$3.946B	$15.91B
YoY Change	11.56%	-25.62%	-8.8%
Operating Profit		$2.059B	$7.489B
YoY Change		924.38%	17.75%
Interest Expense	-$200.0M	$201.0M	$798.0M
YoY Change	4.71%	1.52%	1.79%
% of Operating Profit		9.76%	10.66%
Other Income/Expense, Net
YoY Change
Pretax Income	$1.400B	$1.996B	$7.925B
YoY Change	129.13%	413.11%	27.04%
Income Tax	$275.0M	$494.0M	$1.830B
% Of Pretax Income	19.64%	24.75%	23.09%
Net Earnings	$1.137B	$1.509B	$6.104B
YoY Change	106.35%	579.73%	33.51%
Net Earnings / Revenue	3.11%	4.21%	4.4%
Basic Earnings Per Share		$6.20	$25.04
Diluted Earnings Per Share	$4.629M	$6.13	$24.73
COMMON SHARES
Basic Shares Outstanding	242.7M shares	243.4M shares	243.8M shares
Diluted Shares Outstanding		246.0M shares	246.8M shares

Concept	2021 Q4	2021 Q3	2021
SHORT-TERM ASSETS
Cash & Short-Term Investments	$31.15B	$31.84B
YoY Change	6.76%	19.28%
Cash & Equivalents	$4.880B	$5.490B	$4.880B
Short-Term Investments	$26.27B	$26.35B
Other Short-Term Assets	$4.654B	$5.140B
YoY Change	14.63%	23.95%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$51.12B	$51.90B
YoY Change	11.74%	14.2%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.919B	$3.835B	$4.547B
YoY Change	12.52%	14.04%	10.12%
Goodwill	$24.23B	$24.18B
YoY Change	11.7%	11.51%
Intangibles	$10.62B	$10.75B
YoY Change	12.87%	13.18%
Long-Term Investments	$34.01B	$34.05B	$34.01B
YoY Change	13.96%	11.61%	13.96%
Other Assets	$1.719B	$1.804B
YoY Change	19.54%	-2.43%
Total Long-Term Assets	$46.34B	$46.16B
YoY Change	13.4%	12.24%
TOTAL ASSETS
Total Short-Term Assets	$51.12B	$51.90B
Total Long-Term Assets	$46.34B	$46.16B
Total Assets	$97.46B	$98.06B	$97.46B
YoY Change	12.52%	13.27%	12.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.970B	$5.960B	$4.970B
YoY Change	-9.52%	7.39%	-9.52%
Accrued Expenses	$997.0M	$947.0M	$997.0M
YoY Change	4.18%	-4.34%	4.18%
Deferred Revenue
YoY Change
Short-Term Debt	$275.0M	$175.0M	$275.0M
YoY Change		16.67%
Long-Term Debt Due	$1.599B	$849.0M	$1.599B
YoY Change	128.43%	-46.9%	128.43%
Total Short-Term Liabilities	$34.89B	$35.16B	$7.841B
YoY Change	18.44%	23.11%	9.66%
LONG-TERM LIABILITIES
Long-Term Debt	$21.16B	$21.76B	$21.16B
YoY Change	9.42%	13.97%	9.42%
Other Long-Term Liabilities	$1.683B	$1.912B	$8.535B
YoY Change	-7.27%	3.97%	23.52%
Total Long-Term Liabilities	$22.84B	$23.67B	$29.69B
YoY Change	7.99%	13.09%	13.13%
TOTAL LIABILITIES
Total Short-Term Liabilities	$34.89B	$35.16B	$7.841B
Total Long-Term Liabilities	$22.84B	$23.67B	$29.69B
Total Liabilities	$61.33B	$62.25B	$61.40B
YoY Change	14.82%	18.23%	14.95%
SHAREHOLDERS EQUITY
Retained Earnings	$27.09B	$26.70B
YoY Change	13.81%	8.19%
Common Stock	$2.000M	$2.000M
YoY Change	-33.33%	-33.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$36.06B	$35.74B	$36.06B
YoY Change
Total Liabilities & Shareholders Equity	$97.46B	$98.06B	$97.46B
YoY Change	12.52%	13.27%	12.52%

Concept	2021 Q4	2021 Q3	2021
OPERATING ACTIVITIES
Net Income	$1.137B	$1.509B	$6.104B
YoY Change	106.35%	579.73%	33.51%
Depreciation, Depletion And Amortization	$360.0M	$351.0M	$136.0M
YoY Change	24.14%	13.96%	-22.73%
Cash From Operating Activities	$1.672B	$2.504B	$8.364B
YoY Change	-56.15%	-317.74%	-21.74%
INVESTING ACTIVITIES
Capital Expenditures	-$340.0M	-$258.0M	$1.087B
YoY Change	22.3%	-15.69%	6.46%
Acquisitions			$3.476B
YoY Change			75.91%
Other Investing Activities	-$626.0M	-$1.182B	$63.00M
YoY Change	-207.38%	-399.24%	40.0%
Cash From Investing Activities	-$966.0M	-$1.440B	-$9.638B
YoY Change	-416.72%	-1717.98%	31.59%
FINANCING ACTIVITIES
Cash Dividend Paid	$273.0M	$276.0M	$1.104B
YoY Change	16.67%	15.97%	15.72%
Common Stock Issuance & Retirement, Net			$1.900B
YoY Change			-29.63%
Debt Paid & Issued, Net			$1.068B
YoY Change			-44.72%
Cash From Financing Activities	-1.315B	-830.0M	$423.0M
YoY Change	-44.44%	-15.65%	-116.48%
NET CHANGE
Cash From Operating Activities	1.672B	2.504B	$8.364B
Cash From Investing Activities	-966.0M	-1.440B	-$9.638B
Cash From Financing Activities	-1.315B	-830.0M	$423.0M
Net Change In Cash	-609.0M	234.0M	-$861.0M
YoY Change	-134.78%	-111.44%	-207.09%
FREE CASH FLOW
Cash From Operating Activities	$1.672B	$2.504B	$8.364B
Capital Expenditures	-$340.0M	-$258.0M	$1.087B
Free Cash Flow	$2.012B	$2.762B	$7.277B
YoY Change	-50.82%	-427.25%	-24.72%

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001156039
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q2	dei	Entity Public Float EntityPublicFloat	93007966095	USD
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	241304369	shares
CY2021Q4	antm	Debt Securities Available For Sale Securities Current Amortized Cost Basis DebtSecuritiesAvailableForSaleSecuritiesCurrentAmortizedCostBasis	25641000000	USD
CY2020Q4	antm	Debt Securities Available For Sale Securities Current Amortized Cost Basis DebtSecuritiesAvailableForSaleSecuritiesCurrentAmortizedCostBasis	22222000000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	6000000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	7000000	USD
CY2021Q4	antm	Debt Securities Available For Sale Securities Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleSecuritiesAmortizedCostNoncurrent	616000000	USD
CY2020Q4	antm	Debt Securities Available For Sale Securities Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleSecuritiesAmortizedCostNoncurrent	532000000	USD
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	241770746	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	245401430	shares
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	220 Virginia Avenue
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	241770746	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	245401430	shares
CY2020	antm	Securities Lending Transactions Ratioof Fair Valueof Collateral Held To Securities On Loan SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan	1.02
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent
CY2020Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-16751
CY2021	dei	Entity Registrant Name EntityRegistrantName	ANTHEM, INC.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	IN
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	35-2145715
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Indianapolis
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	IN
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	46204
CY2021	dei	City Area Code CityAreaCode	(800)
CY2021	dei	Local Phone Number LocalPhoneNumber	331-1476
CY2021	dei	Security12b Title Security12bTitle	Common Stock, Par Value $0.01
CY2021	dei	Trading Symbol TradingSymbol	ANTM
CY2021	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	false
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	93007966095	USD
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	241304369	shares
CY2021	dei	Auditor Firm AuditorFirmId	42
CY2021	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2021	dei	Auditor Location AuditorLocation	Indianapolis, Indiana
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4880000000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5741000000	USD
CY2021Q4	antm	Debt Securities Available For Sale Securities Current Amortized Cost Basis DebtSecuritiesAvailableForSaleSecuritiesCurrentAmortizedCostBasis	25641000000	USD
CY2020Q4	antm	Debt Securities Available For Sale Securities Current Amortized Cost Basis DebtSecuritiesAvailableForSaleSecuritiesCurrentAmortizedCostBasis	22222000000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	6000000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	7000000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	26267000000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	23433000000	USD
CY2021Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	1881000000	USD
CY2020Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	1559000000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3919000000	USD
CY2021Q4	us-gaap	Premiums Receivable At Carrying Value PremiumsReceivableAtCarryingValue	5681000000	USD
CY2020Q4	us-gaap	Premiums Receivable At Carrying Value PremiumsReceivableAtCarryingValue	5279000000	USD
CY2021Q4	antm	Self Funded Receivables Net SelfFundedReceivablesNet	4010000000	USD
CY2020Q4	antm	Self Funded Receivables Net SelfFundedReceivablesNet	2849000000	USD
CY2021Q4	us-gaap	Other Receivables OtherReceivables	3749000000	USD
CY2020Q4	us-gaap	Other Receivables OtherReceivables	2830000000	USD
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	4654000000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	4060000000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	51122000000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	45751000000	USD
CY2021Q4	antm	Debt Securities Available For Sale Securities Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleSecuritiesAmortizedCostNoncurrent	616000000	USD
CY2020Q4	antm	Debt Securities Available For Sale Securities Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleSecuritiesAmortizedCostNoncurrent	532000000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	632000000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	562000000	USD
CY2021Q4	us-gaap	Other Long Term Investments OtherLongTermInvestments	5225000000	USD
CY2020Q4	us-gaap	Other Long Term Investments OtherLongTermInvestments	4285000000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3483000000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	24228000000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	21691000000	USD
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	10615000000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	9405000000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1719000000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1438000000	USD
CY2021Q4	us-gaap	Assets Assets	97460000000	USD
CY2020Q4	us-gaap	Assets Assets	86615000000	USD
CY2021Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	13518000000	USD
CY2020Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	11359000000	USD
CY2021Q4	us-gaap	Other Policyholder Funds OtherPolicyholderFunds	5521000000	USD
CY2020Q4	us-gaap	Other Policyholder Funds OtherPolicyholderFunds	4590000000	USD
CY2021Q4	us-gaap	Unearned Premiums UnearnedPremiums	1153000000	USD
CY2020Q4	us-gaap	Unearned Premiums UnearnedPremiums	1259000000	USD
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	4970000000	USD
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	5493000000	USD
CY2021Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	275000000	USD
CY2020Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	0	USD
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1599000000	USD
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	700000000	USD
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	7849000000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	6052000000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	34885000000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	29453000000	USD
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	21157000000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	19335000000	USD
CY2021Q4	us-gaap	Liability For Future Policy Benefits LiabilityForFuturePolicyBenefits	802000000	USD
CY2020Q4	us-gaap	Liability For Future Policy Benefits LiabilityForFuturePolicyBenefits	794000000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	2805000000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	2019000000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1683000000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1815000000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	61332000000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	53416000000	USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	241770746	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	245401430	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	2000000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	3000000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	9148000000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	9244000000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	27088000000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	23802000000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-178000000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	150000000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	36060000000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	33199000000	USD
CY2021Q4	us-gaap	Minority Interest MinorityInterest	68000000	USD
CY2020Q4	us-gaap	Minority Interest MinorityInterest	0	USD
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	36128000000	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	33199000000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	97460000000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	86615000000	USD
CY2021	us-gaap	Premiums Earned Net PremiumsEarnedNet	117373000000	USD
CY2020	us-gaap	Premiums Earned Net PremiumsEarnedNet	104109000000	USD
CY2019	us-gaap	Premiums Earned Net PremiumsEarnedNet	94173000000	USD
CY2021	antm	Product Revenue ProductRevenue	12657000000	USD
CY2020	antm	Product Revenue ProductRevenue	10384000000	USD
CY2019	antm	Product Revenue ProductRevenue	2760000000	USD
CY2021	us-gaap	Other Income OtherIncome	6913000000	USD
CY2020	us-gaap	Other Income OtherIncome	6315000000	USD
CY2019	us-gaap	Other Income OtherIncome	6208000000	USD
CY2021	antm	Operating Revenue OperatingRevenue	136943000000	USD
CY2020	antm	Operating Revenue OperatingRevenue	120808000000	USD
CY2019	antm	Operating Revenue OperatingRevenue	103141000000	USD
CY2021	us-gaap	Net Investment Income NetInvestmentIncome	1378000000	USD
CY2020	us-gaap	Net Investment Income NetInvestmentIncome	877000000	USD
CY2019	us-gaap	Net Investment Income NetInvestmentIncome	1005000000	USD
CY2021	antm	Net Gains Losses On Financial Instruments NetGainsLossesOnFinancialInstruments	318000000	USD
CY2020	antm	Net Gains Losses On Financial Instruments NetGainsLossesOnFinancialInstruments	182000000	USD
CY2019	antm	Net Gains Losses On Financial Instruments NetGainsLossesOnFinancialInstruments	67000000	USD
CY2021	us-gaap	Revenues Revenues	138639000000	USD
CY2020	us-gaap	Revenues Revenues	121867000000	USD
CY2019	us-gaap	Revenues Revenues	104213000000	USD
CY2021	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	102645000000	USD
CY2020	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	88045000000	USD
CY2019	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	81786000000	USD
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	10895000000	USD
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	8953000000	USD
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1992000000	USD
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	15914000000	USD
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	17450000000	USD
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	13364000000	USD
CY2021	us-gaap	Interest Expense InterestExpense	798000000	USD
CY2020	us-gaap	Interest Expense InterestExpense	784000000	USD
CY2019	us-gaap	Interest Expense InterestExpense	746000000	USD
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	441000000	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	361000000	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	338000000	USD
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-21000000	USD
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-36000000	USD
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-2000000	USD
CY2021	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	130714000000	USD
CY2020	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	115629000000	USD
CY2019	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	98228000000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	7925000000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	6238000000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	5985000000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1830000000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1666000000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1178000000	USD
CY2021	us-gaap	Profit Loss ProfitLoss	6095000000	USD
CY2020	us-gaap	Profit Loss ProfitLoss	4572000000	USD
CY2019	us-gaap	Profit Loss ProfitLoss	4807000000	USD
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-9000000	USD
CY2020	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	USD
CY2019	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	6104000000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	4572000000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	4807000000	USD
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	25.04
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	18.23
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	18.81
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	24.73
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	17.98
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	18.47
CY2021	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	4.52
CY2020	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	3.80
CY2019	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	3.20
CY2021	us-gaap	Profit Loss ProfitLoss	6095000000	USD
CY2020	us-gaap	Profit Loss ProfitLoss	4572000000	USD
CY2019	us-gaap	Profit Loss ProfitLoss	4807000000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-457000000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	428000000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	680000000	USD
CY2021	us-gaap	Other Than Temporary Impairment Losses Investments Portion In Other Comprehensive Income Loss Net Of Tax Including Portion Attributable To Noncontrolling Interest Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities	2000000	USD
CY2020	us-gaap	Other Than Temporary Impairment Losses Investments Portion In Other Comprehensive Income Loss Net Of Tax Including Portion Attributable To Noncontrolling Interest Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities	0	USD
CY2019	us-gaap	Other Than Temporary Impairment Losses Investments Portion In Other Comprehensive Income Loss Net Of Tax Including Portion Attributable To Noncontrolling Interest Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities	0	USD
CY2021	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	11000000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	12000000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	-16000000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-123000000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	1000000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-26000000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-9000000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	7000000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	0	USD
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-330000000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	446000000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	690000000	USD
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-9000000	USD
CY2020	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	USD
CY2019	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	USD
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	-2000000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	0	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	0	USD
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	5776000000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	5018000000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	5497000000	USD
CY2021	us-gaap	Profit Loss ProfitLoss	6095000000	USD
CY2020	us-gaap	Profit Loss ProfitLoss	4572000000	USD
CY2019	us-gaap	Profit Loss ProfitLoss	4807000000	USD
CY2021	antm	Net Gains Losses On Financial Instruments NetGainsLossesOnFinancialInstruments	318000000	USD
CY2020	antm	Net Gains Losses On Financial Instruments NetGainsLossesOnFinancialInstruments	182000000	USD
CY2019	antm	Net Gains Losses On Financial Instruments NetGainsLossesOnFinancialInstruments	67000000	USD
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	562000000	USD
CY2020	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	51000000	USD
CY2019	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	93000000	USD
CY2021	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	1302000000	USD
CY2020	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	1154000000	USD
CY2019	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	1133000000	USD
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	326000000	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-540000000	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	81000000	USD
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	73000000	USD
CY2020	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	198000000	USD
CY2019	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	255000000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	283000000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	294000000	USD
CY2021	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	2138000000	USD
CY2020	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	256000000	USD
CY2019	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	1053000000	USD
CY2021	us-gaap	Increase Decrease In Trading Securities IncreaseDecreaseInTradingSecurities	70000000	USD
CY2020	us-gaap	Increase Decrease In Trading Securities IncreaseDecreaseInTradingSecurities	32000000	USD
CY2019	us-gaap	Increase Decrease In Trading Securities IncreaseDecreaseInTradingSecurities	48000000	USD
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-37000000	USD
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	283000000	USD
CY2019	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	170000000	USD
CY2021	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	2597000000	USD
CY2020	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	3528000000	USD
CY2019	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	1826000000	USD
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-113000000	USD
CY2019	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	22954000000	USD
CY2020	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	202000000	USD
CY2019	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	115000000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	719000000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	1978000000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	-445000000	USD
CY2021	us-gaap	Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable	140000000	USD
CY2020	us-gaap	Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable	72000000	USD
CY2019	us-gaap	Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable	-325000000	USD
CY2021	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-21000000	USD
CY2020	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-45000000	USD
CY2019	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-6000000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	8364000000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	10688000000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	6061000000	USD
CY2021	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	18669000000	USD
CY2020	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	19492000000	USD
CY2021	antm	Proceedsfromsaleofequityandfixedmaturitysecurities Proceedsfromsaleofequityandfixedmaturitysecurities	10269000000	USD
CY2020	antm	Proceedsfromsaleofequityandfixedmaturitysecurities Proceedsfromsaleofequityandfixedmaturitysecurities	11318000000	USD
CY2019	antm	Proceedsfromsaleofequityandfixedmaturitysecurities Proceedsfromsaleofequityandfixedmaturitysecurities	18598000000	USD
CY2021	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	4344000000	USD
CY2020	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	4741000000	USD
CY2019	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	2437000000	USD
CY2021	us-gaap	Increase Decrease In Collateral Held Under Securities Lending IncreaseDecreaseInCollateralHeldUnderSecuritiesLending	956000000	USD
CY2020	us-gaap	Increase Decrease In Collateral Held Under Securities Lending IncreaseDecreaseInCollateralHeldUnderSecuritiesLending	849000000	USD
CY2019	us-gaap	Increase Decrease In Collateral Held Under Securities Lending IncreaseDecreaseInCollateralHeldUnderSecuritiesLending	-254000000	USD
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	3476000000	USD
CY2020	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	1976000000	USD
CY2019	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1087000000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1021000000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1077000000	USD
CY2021	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	63000000	USD
CY2020	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	45000000	USD
CY2019	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	50000000	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-9638000000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7324000000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2792000000	USD
CY2021	us-gaap	Proceeds From Repayments Of Commercial Paper ProceedsFromRepaymentsOfCommercialPaper	50000000	USD
CY2020	us-gaap	Proceeds From Repayments Of Commercial Paper ProceedsFromRepaymentsOfCommercialPaper	-150000000	USD
CY2019	us-gaap	Proceeds From Repayments Of Commercial Paper ProceedsFromRepaymentsOfCommercialPaper	-297000000	USD
CY2021	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	3462000000	USD
CY2020	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	2484000000	USD
CY2019	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	2473000000	USD
CY2021	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1068000000	USD
CY2020	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1932000000	USD
CY2019	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1123000000	USD
CY2021	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	1325000000	USD
CY2020	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	970000000	USD
CY2019	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	7590000000	USD
CY2021	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	1050000000	USD
CY2020	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	1670000000	USD
CY2019	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	8035000000	USD
CY2021	us-gaap	Increase Decrease In Securities Lending Payable IncreaseDecreaseInSecuritiesLendingPayable	956000000	USD
CY2020	us-gaap	Increase Decrease In Securities Lending Payable IncreaseDecreaseInSecuritiesLendingPayable	849000000	USD
CY2019	us-gaap	Increase Decrease In Securities Lending Payable IncreaseDecreaseInSecuritiesLendingPayable	-254000000	USD
CY2021	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1900000000	USD
CY2020	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	2700000000	USD
CY2019	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1701000000	USD
CY2021	us-gaap	Payments Of Dividends PaymentsOfDividends	1104000000	USD
CY2020	us-gaap	Payments Of Dividends PaymentsOfDividends	954000000	USD
CY2019	us-gaap	Payments Of Dividends PaymentsOfDividends	818000000	USD
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	203000000	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	176000000	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	187000000	USD
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	102000000	USD
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	128000000	USD
CY2019	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	84000000	USD
CY2021	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-349000000	USD
CY2020	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	488000000	USD
CY2019	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-204000000	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	423000000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2567000000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2266000000	USD
CY2021	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-10000000	USD
CY2020	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	7000000	USD
CY2019	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	0	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-861000000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	804000000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1003000000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5741000000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4937000000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3934000000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4880000000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5741000000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4937000000	USD
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	28567000000	USD
CY2019	us-gaap	Profit Loss ProfitLoss	4807000000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	690000000	USD
CY2019	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	1701000000	USD
CY2019	us-gaap	Dividends Common Stock DividendsCommonStock	822000000	USD
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	396000000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments	-209000000	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	31728000000	USD
CY2020	us-gaap	Profit Loss ProfitLoss	4572000000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	446000000	USD
CY2020	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	2700000000	USD
CY2020	us-gaap	Dividends Common Stock DividendsCommonStock	961000000	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	330000000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments	-181000000	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	33199000000	USD
CY2021	us-gaap	Profit Loss ProfitLoss	6095000000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-330000000	USD
CY2021	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	79000000	USD
CY2021	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	1900000000	USD
CY2021	us-gaap	Dividends Common Stock DividendsCommonStock	1111000000	USD
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	355000000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments	-259000000	USD
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	36128000000	USD
CY2021	us-gaap	Nature Of Operations NatureOfOperations	Organization <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to the terms “we,” “our,” “us” or “Anthem” used throughout these Notes to Consolidated Financial Statements refer to Anthem, Inc., an Indiana corporation, and unless the context otherwise requires, its direct and indirect subsidiaries. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are one of the largest health benefits companies in the United States in terms of medical membership, serving greater than 45 million medical members through our affiliated health plans as of December 31, 2021. We offer a broad spectrum of network-based managed care risk-based plans to Individual, Group, Medicaid and Medicare markets. In addition, we provide a broad array of managed care services to fee-based customers, including claims processing, stop loss insurance, provider network access, medical management, care management and wellness programs, actuarial services and other administrative services. We also provide services to the federal government in connection with our Federal Health Products & Services business, which administers the Federal Employees Health Benefits (“FEHB”) Program. We provide an array of specialty services both to our subsidiary health plans and also unaffiliated health plans, including pharmacy benefit management (“PBM”) services and dental, vision, life, disability and supplemental health insurance benefits, as well as integrated health services.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an independent licensee of the Blue Cross and Blue Shield Association (“BCBSA”), an association of independent health benefit plans. We serve our members as the Blue Cross licensee for California and as the Blue Cross and Blue Shield (“BCBS”) licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding 30 counties in the Kansas City area), Nevada, New Hampshire, New York (in the New York City metropolitan area and upstate New York), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a majority of these service areas, we do business as Anthem Blue Cross, Anthem Blue Cross and Blue Shield, and Empire Blue Cross Blue Shield or Empire Blue Cross. We also conduct business through arrangements with other BCBS licensees as well as other strategic partners. Through our subsidiaries, we also serve customers in numerous states and Puerto Rico as AIM Specialty Health, Amerigroup, Aspire Health, Beacon, CareMore, Freedom Health, HealthLink, HealthSun, MMM, Optimum HealthCare, Simply Healthcare, and/or UniCare. PBM services are offered through our IngenioRx, Inc. (“IngenioRx”) subsidiary. We are licensed to conduct insurance operations in all 50 states, the District of Columbia and Puerto Rico through our subsidiaries.</span></div>
CY2021Q4	antm	Number Of Medical Members Served NumberOfMedicalMembersServed	45000000	individuals
CY2021Q4	antm	Number Of Counties In Geographical Region Not Served NumberOfCountiesInGeographicalRegionNotServed	30	counties
CY2021Q4	us-gaap	Number Of States In Which Entity Operates NumberOfStatesInWhichEntityOperates	50	states
CY2021	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Certain prior year amounts have been reclassified to conform to the current year presentation.</span>
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Our most significant estimate relates to estimates and judgments for medical claims payable. Actual results could differ from those estimates.</span>
CY2021Q4	us-gaap	Restricted Cash And Investments Current RestrictedCashAndInvestmentsCurrent	173000000	USD
CY2020Q4	us-gaap	Restricted Cash And Investments Current RestrictedCashAndInvestmentsCurrent	170000000	USD
CY2021	antm	Securities Lending Transactions Ratioof Fair Valueof Collateral Held To Securities On Loan SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan	1.02
CY2021Q4	us-gaap	Premiums Receivable Allowance For Doubtful Accounts PremiumsReceivableAllowanceForDoubtfulAccounts	142000000	USD
CY2020Q4	us-gaap	Premiums Receivable Allowance For Doubtful Accounts PremiumsReceivableAllowanceForDoubtfulAccounts	146000000	USD
CY2021Q4	antm	Selffunded Receivables Allowance For Doubtful Accounts SelffundedReceivablesAllowanceForDoubtfulAccounts	50000000	USD
CY2020Q4	antm	Selffunded Receivables Allowance For Doubtful Accounts SelffundedReceivablesAllowanceForDoubtfulAccounts	54000000	USD
CY2021Q4	us-gaap	Allowance For Doubtful Other Receivables Current AllowanceForDoubtfulOtherReceivablesCurrent	648000000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Other Receivables Current AllowanceForDoubtfulOtherReceivablesCurrent	374000000	USD
CY2021	us-gaap	Defined Benefit Plan Alternative Method Used To Amortize Net Gains And Losses DefinedBenefitPlanAlternativeMethodUsedToAmortizeNetGainsAndLosses	We determine the expected return on plan assets using the calculated value of plan assets, which recognizes changes in the fair value of plan assets in a systematic manner over three years. We apply a corridor approach to amortize unrecognized actuarial gains or losses. Under this approach, only accumulated net actuarial gains or losses in excess of 10% of the greater of the projected benefit obligation or the fair value of plan assets are amortized over the average remaining service or lifetime of the workforce as a component of net periodic benefit cost.
CY2020	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	558000000	USD
CY2019	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	467000000	USD
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	0.90
CY2021	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	588000000	USD
CY2020Q4	antm	Patient Protection Affordable Care Act Health Insurance Provider Fee PatientProtectionAffordableCareActHealthInsuranceProviderFee	15523000000	USD
CY2020	antm	Patient Protection Affordable Care Act Health Insurance Provider Fee Amount Paid PatientProtectionAffordableCareActHealthInsuranceProviderFeeAmountPaid	1570000000	USD
CY2021	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	136000000	USD
CY2020	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	258000000	USD
CY2021	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	4021000000	USD
CY2021	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	1577000000	USD
CY2021	us-gaap	Indefinitelived Intangible Assets Acquired IndefinitelivedIntangibleAssetsAcquired	20000000	USD
CY2021	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	2521000000	USD
CY2021Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	808000000	USD
CY2020Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	659000000	USD
CY2021Q4	antm	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Accounts Receivables And Other Current Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAccountsReceivablesAndOtherCurrentAssets	295000000	USD
CY2020Q4	antm	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Accounts Receivables And Other Current Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAccountsReceivablesAndOtherCurrentAssets	282000000	USD
CY2021Q4	antm	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property And Equipment And Other Long Term Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyAndEquipmentAndOtherLongTermAssets	102000000	USD
CY2020Q4	antm	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property And Equipment And Other Long Term Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyAndEquipmentAndOtherLongTermAssets	296000000	USD
CY2021Q4	antm	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Medical Claims And Other Policyholder Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMedicalClaimsAndOtherPolicyholderLiabilities	571000000	USD
CY2020Q4	antm	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Medical Claims And Other Policyholder Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMedicalClaimsAndOtherPolicyholderLiabilities	580000000	USD
CY2021Q4	antm	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable And Other Current Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherCurrentLiabilities	179000000	USD
CY2020Q4	antm	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable And Other Current Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherCurrentLiabilities	257000000	USD
CY2021Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Liabilities Other BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther	6000000	USD
CY2020Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Liabilities Other BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther	49000000	USD
CY2021Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet	449000000	USD
CY2020Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet	351000000	USD
CY2021Q4	antm	Total Intangible Assets Acquired TotalIntangibleAssetsAcquired	1597000000	USD
CY2020Q4	antm	Total Intangible Assets Acquired TotalIntangibleAssetsAcquired	1092000000	USD
CY2021	us-gaap	Restructuring And Related Cost Incurred Cost RestructuringAndRelatedCostIncurredCost	202000000	USD
CY2020	us-gaap	Restructuring And Related Cost Incurred Cost RestructuringAndRelatedCostIncurredCost	653000000	USD
CY2021Q4	antm	Equity Securities EquitySecurities	1881000000	USD
CY2020Q4	antm	Equity Securities EquitySecurities	1559000000	USD
CY2021	us-gaap	Investment Income Net InvestmentIncomeNet	1419000000	USD
CY2020	us-gaap	Investment Income Net InvestmentIncomeNet	915000000	USD
CY2019	us-gaap	Investment Income Net InvestmentIncomeNet	1034000000	USD
CY2021	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	41000000	USD
CY2020	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	38000000	USD
CY2019	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	29000000	USD
CY2021	us-gaap	Net Investment Income NetInvestmentIncome	1378000000	USD
CY2020	us-gaap	Net Investment Income NetInvestmentIncome	877000000	USD
CY2019	us-gaap	Net Investment Income NetInvestmentIncome	1005000000	USD
CY2021	antm	Investment Gains Losses InvestmentGainsLosses	311000000	USD
CY2020	antm	Investment Gains Losses InvestmentGainsLosses	184000000	USD
CY2019	antm	Investment Gains Losses InvestmentGainsLosses	84000000	USD
CY2021	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-71000000	USD
CY2020	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	194000000	USD
CY2019	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	63000000	USD
CY2021	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	-73000000	USD
CY2020	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	61000000	USD
CY2019	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	39000000	USD
CY2021	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	2000000	USD
CY2020	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	133000000	USD
CY2019	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	24000000	USD
CY2021Q4	antm	Number Of Fixed Maturity Investments That Did Not Produce Income NumberOfFixedMaturityInvestmentsThatDidNotProduceIncome	2
CY2020Q4	antm	Number Of Fixed Maturity Investments That Did Not Produce Income NumberOfFixedMaturityInvestmentsThatDidNotProduceIncome	3
CY2021Q4	us-gaap	Contractual Obligation ContractualObligation	1558000000	USD
CY2020Q4	us-gaap	Contractual Obligation ContractualObligation	1320000000	USD
CY2021Q4	us-gaap	Assets Held By Insurance Regulators AssetsHeldByInsuranceRegulators	632000000	USD
CY2020Q4	us-gaap	Assets Held By Insurance Regulators AssetsHeldByInsuranceRegulators	562000000	USD
CY2021Q4	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	205000000	USD
CY2020Q4	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	188000000	USD
CY2021Q4	us-gaap	Securities Loaned Fair Value Of Collateral SecuritiesLoanedFairValueOfCollateral	2155000000	USD
CY2020Q4	us-gaap	Securities Loaned Fair Value Of Collateral SecuritiesLoanedFairValueOfCollateral	1199000000	USD
CY2021	antm	Securities Lending Transactions Ratioof Fair Valueof Collateral Held To Securities On Loan SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan	1.02
CY2021Q4	us-gaap	Derivative Asset Collateral Obligation To Return Cash Offset DerivativeAssetCollateralObligationToReturnCashOffset	18000000	USD
CY2020Q4	us-gaap	Derivative Asset Collateral Obligation To Return Cash Offset DerivativeAssetCollateralObligationToReturnCashOffset	37000000	USD
CY2021Q4	us-gaap	Derivative Notional Amount DerivativeNotionalAmount	1407000000	USD
CY2021Q4	us-gaap	Derivative Fair Value Of Derivative Asset DerivativeFairValueOfDerivativeAsset	47000000	USD
CY2021Q4	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	29000000	USD
CY2021Q4	us-gaap	Derivative Asset Fair Value Gross Liability DerivativeAssetFairValueGrossLiability	21000000	USD
CY2021Q4	us-gaap	Derivative Liability Fair Value Gross Asset DerivativeLiabilityFairValueGrossAsset	21000000	USD
CY2021Q4	us-gaap	Derivative Fair Value Of Derivative Asset Amount Not Offset Against Collateral DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral	26000000	USD
CY2021Q4	us-gaap	Derivative Fair Value Of Derivative Liability Amount Not Offset Against Collateral DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral	8000000	USD
CY2020Q4	us-gaap	Derivative Notional Amount DerivativeNotionalAmount	785000000	USD
CY2020Q4	us-gaap	Derivative Fair Value Of Derivative Asset DerivativeFairValueOfDerivativeAsset	43000000	USD
CY2020Q4	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	5000000	USD
CY2020Q4	us-gaap	Derivative Asset Fair Value Gross Liability DerivativeAssetFairValueGrossLiability	0	USD
CY2020Q4	us-gaap	Derivative Liability Fair Value Gross Asset DerivativeLiabilityFairValueGrossAsset	0	USD
CY2020Q4	us-gaap	Derivative Fair Value Of Derivative Asset Amount Not Offset Against Collateral DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral	43000000	USD
CY2020Q4	us-gaap	Derivative Fair Value Of Derivative Liability Amount Not Offset Against Collateral DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral	5000000	USD
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	7000000	USD
CY2020	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-2000000	USD
CY2019	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-17000000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	2415000000	USD
CY2021Q4	us-gaap	Securities Held As Collateral At Fair Value SecuritiesHeldAsCollateralAtFairValue	2155000000	USD
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	33507000000	USD
CY2021Q4	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	1000000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	3163000000	USD
CY2020Q4	us-gaap	Securities Held As Collateral At Fair Value SecuritiesHeldAsCollateralAtFairValue	1199000000	USD
CY2020Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	29959000000	USD

CY2021

dei

Amendment Flag

AmendmentFlag

false

CY2021

dei

Document Period End Date

DocumentPeriodEndDate

2021-12-31

CY2021

dei

Document Fiscal Year Focus

DocumentFiscalYearFocus

2021

CY2021

dei

Document Fiscal Period Focus

DocumentFiscalPeriodFocus

FY

CY2021

dei

Entity Central Index Key

EntityCentralIndexKey

0001156039

CY2021

dei

Current Fiscal Year End Date

CurrentFiscalYearEndDate

--12-31

CY2021Q2

dei

Entity Public Float

EntityPublicFloat

93007966095

USD

CY2022Q1

dei

Entity Common Stock Shares Outstanding

EntityCommonStockSharesOutstanding

241304369

shares

CY2021Q4

antm

Debt Securities Available For Sale Securities Current Amortized Cost Basis

DebtSecuritiesAvailableForSaleSecuritiesCurrentAmortizedCostBasis

25641000000

USD

CY2020Q4

antm

Debt Securities Available For Sale Securities Current Amortized Cost Basis

DebtSecuritiesAvailableForSaleSecuritiesCurrentAmortizedCostBasis

22222000000

USD

CY2021Q4

us-gaap

Debt Securities Available For Sale Allowance For Credit Loss

DebtSecuritiesAvailableForSaleAllowanceForCreditLoss

6000000

USD

CY2020Q4

us-gaap

Debt Securities Available For Sale Allowance For Credit Loss

DebtSecuritiesAvailableForSaleAllowanceForCreditLoss

7000000

USD

CY2021Q4

antm

Debt Securities Available For Sale Securities Amortized Cost Noncurrent

DebtSecuritiesAvailableForSaleSecuritiesAmortizedCostNoncurrent

616000000

USD

CY2020Q4

antm

Debt Securities Available For Sale Securities Amortized Cost Noncurrent

DebtSecuritiesAvailableForSaleSecuritiesAmortizedCostNoncurrent

532000000

USD

CY2021Q4

us-gaap

Preferred Stock Par Or Stated Value Per Share

PreferredStockParOrStatedValuePerShare

0

CY2020Q4

us-gaap

Preferred Stock Par Or Stated Value Per Share

PreferredStockParOrStatedValuePerShare

0

CY2021Q4

us-gaap

Preferred Stock Shares Authorized

PreferredStockSharesAuthorized

100000000

shares

CY2020Q4

us-gaap

Preferred Stock Shares Authorized

PreferredStockSharesAuthorized

100000000

shares

CY2021Q4

us-gaap

Preferred Stock Shares Issued

PreferredStockSharesIssued

0

shares

CY2020Q4

us-gaap

Preferred Stock Shares Issued

PreferredStockSharesIssued

0

shares

CY2021Q4

us-gaap

Preferred Stock Shares Outstanding

PreferredStockSharesOutstanding

0

shares

CY2020Q4

us-gaap

Preferred Stock Shares Outstanding

PreferredStockSharesOutstanding

0

shares

CY2021Q4

us-gaap

Common Stock Par Or Stated Value Per Share

CommonStockParOrStatedValuePerShare

0.01

CY2020Q4

us-gaap

Common Stock Par Or Stated Value Per Share

CommonStockParOrStatedValuePerShare

0.01

CY2021Q4

us-gaap

Common Stock Shares Authorized

CommonStockSharesAuthorized

900000000

shares

CY2020Q4

us-gaap

Common Stock Shares Authorized

CommonStockSharesAuthorized

900000000

shares

CY2021Q4

us-gaap

Common Stock Shares Issued

CommonStockSharesIssued

241770746

shares

CY2020Q4

us-gaap

Common Stock Shares Issued

CommonStockSharesIssued

245401430

shares

CY2021

dei

Entity Interactive Data Current

EntityInteractiveDataCurrent

Yes

CY2021

dei

Entity Address Address Line1

EntityAddressAddressLine1

220 Virginia Avenue

CY2021Q4

us-gaap

Common Stock Shares Outstanding

CommonStockSharesOutstanding

241770746

shares

CY2020Q4

us-gaap

Common Stock Shares Outstanding

CommonStockSharesOutstanding

245401430

shares

CY2020

antm

Securities Lending Transactions Ratioof Fair Valueof Collateral Held To Securities On Loan

SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan

1.02

CY2021Q4

us-gaap

Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List

OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList

http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent

CY2021Q4

us-gaap

Operating Lease Liability Current Statement Of Financial Position Extensible List

OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList

http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent

CY2021Q4

us-gaap

Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List

OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList

http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent

CY2020Q4

us-gaap

Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List

OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList

http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent

CY2020Q4

us-gaap

Operating Lease Liability Current Statement Of Financial Position Extensible List

OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList

http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent

CY2020Q4

us-gaap

Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List

OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList

http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent

CY2021

dei

Document Type

DocumentType

10-K

CY2021

dei

Document Annual Report

DocumentAnnualReport

true

CY2021

dei

Document Transition Report

DocumentTransitionReport

false

CY2021

dei

Entity File Number

EntityFileNumber

001-16751

CY2021

dei

Entity Registrant Name

EntityRegistrantName

ANTHEM, INC.

CY2021

dei

Entity Incorporation State Country Code

EntityIncorporationStateCountryCode

IN

CY2021

dei

Entity Tax Identification Number

EntityTaxIdentificationNumber

35-2145715

CY2021

dei

Entity Address City Or Town

EntityAddressCityOrTown

Indianapolis

CY2021

dei

Entity Address State Or Province

EntityAddressStateOrProvince

IN

CY2021

dei

Entity Address Postal Zip Code

EntityAddressPostalZipCode

46204

CY2021

dei

City Area Code

CityAreaCode

(800)

CY2021

dei

Local Phone Number

LocalPhoneNumber

331-1476

CY2021

dei

Security12b Title

Security12bTitle

Common Stock, Par Value $0.01

CY2021

dei

Trading Symbol

TradingSymbol

ANTM

CY2021

dei

Security Exchange Name

SecurityExchangeName

NYSE

CY2021

dei

Entity Well Known Seasoned Issuer

EntityWellKnownSeasonedIssuer

Yes

CY2021

dei

Entity Voluntary Filers

EntityVoluntaryFilers

No

CY2021

dei

Entity Current Reporting Status

EntityCurrentReportingStatus

Yes

CY2021

dei

Entity Filer Category

EntityFilerCategory

Large Accelerated Filer

CY2021

dei

Entity Small Business

EntitySmallBusiness

false

CY2021

dei

Entity Emerging Growth Company

EntityEmergingGrowthCompany

false

CY2021

dei

Icfr Auditor Attestation Flag

IcfrAuditorAttestationFlag

true

CY2021

dei

Entity Shell Company

EntityShellCompany

false

CY2021Q2

dei

Entity Public Float

EntityPublicFloat

93007966095

USD

CY2022Q1

dei

Entity Common Stock Shares Outstanding

EntityCommonStockSharesOutstanding

241304369

shares

CY2021

dei

Auditor Firm

AuditorFirmId

42

CY2021

dei

Auditor Name

AuditorName

Ernst & Young LLP

CY2021

dei

Auditor Location

AuditorLocation

Indianapolis, Indiana

CY2021Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

4880000000

USD

CY2020Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

5741000000

USD

CY2021Q4

antm

Debt Securities Available For Sale Securities Current Amortized Cost Basis

DebtSecuritiesAvailableForSaleSecuritiesCurrentAmortizedCostBasis

25641000000

USD

CY2020Q4

antm

Debt Securities Available For Sale Securities Current Amortized Cost Basis

DebtSecuritiesAvailableForSaleSecuritiesCurrentAmortizedCostBasis

22222000000

USD

CY2021Q4

us-gaap

Debt Securities Available For Sale Allowance For Credit Loss

DebtSecuritiesAvailableForSaleAllowanceForCreditLoss

6000000

USD

CY2020Q4

us-gaap

Debt Securities Available For Sale Allowance For Credit Loss

DebtSecuritiesAvailableForSaleAllowanceForCreditLoss

7000000

USD

CY2021Q4

us-gaap

Available For Sale Securities Debt Securities Current

AvailableForSaleSecuritiesDebtSecuritiesCurrent

26267000000

USD

CY2020Q4

us-gaap

Available For Sale Securities Debt Securities Current

AvailableForSaleSecuritiesDebtSecuritiesCurrent

23433000000

USD

CY2021Q4

us-gaap

Equity Securities Fv Ni

EquitySecuritiesFvNi

1881000000

USD

CY2020Q4

us-gaap

Equity Securities Fv Ni

EquitySecuritiesFvNi

1559000000

USD

CY2021Q4

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

3919000000

USD

CY2021Q4

us-gaap

Premiums Receivable At Carrying Value

PremiumsReceivableAtCarryingValue

5681000000

USD

CY2020Q4

us-gaap

Premiums Receivable At Carrying Value

PremiumsReceivableAtCarryingValue

5279000000

USD

CY2021Q4

antm

Self Funded Receivables Net

SelfFundedReceivablesNet

4010000000

USD

CY2020Q4

antm

Self Funded Receivables Net

SelfFundedReceivablesNet

2849000000

USD

CY2021Q4

us-gaap

Other Receivables

OtherReceivables

3749000000

USD

CY2020Q4

us-gaap

Other Receivables

OtherReceivables

2830000000

USD

CY2021Q4

us-gaap

Other Assets Current

OtherAssetsCurrent

4654000000

USD

CY2020Q4

us-gaap

Other Assets Current

OtherAssetsCurrent

4060000000

USD

CY2021Q4

us-gaap

Assets Current

AssetsCurrent

51122000000

USD

CY2020Q4

us-gaap

Assets Current

AssetsCurrent

45751000000

USD

CY2021Q4

antm

Debt Securities Available For Sale Securities Amortized Cost Noncurrent

DebtSecuritiesAvailableForSaleSecuritiesAmortizedCostNoncurrent

616000000

USD

CY2020Q4

antm

Debt Securities Available For Sale Securities Amortized Cost Noncurrent

DebtSecuritiesAvailableForSaleSecuritiesAmortizedCostNoncurrent

532000000

USD

CY2021Q4

us-gaap

Available For Sale Securities Debt Securities Noncurrent

AvailableForSaleSecuritiesDebtSecuritiesNoncurrent

632000000

USD

CY2020Q4

us-gaap

Available For Sale Securities Debt Securities Noncurrent

AvailableForSaleSecuritiesDebtSecuritiesNoncurrent

562000000

USD

CY2021Q4

us-gaap

Other Long Term Investments

OtherLongTermInvestments

5225000000

USD

CY2020Q4

us-gaap

Other Long Term Investments

OtherLongTermInvestments

4285000000

USD

CY2020Q4

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

3483000000

USD

CY2021Q4

us-gaap

Goodwill

24228000000

USD

CY2020Q4

us-gaap

Goodwill

21691000000

USD

CY2021Q4

us-gaap

Intangible Assets Net Excluding Goodwill

IntangibleAssetsNetExcludingGoodwill

10615000000

USD

CY2020Q4

us-gaap

Intangible Assets Net Excluding Goodwill

IntangibleAssetsNetExcludingGoodwill

9405000000

USD

CY2021Q4

us-gaap

Other Assets Noncurrent

OtherAssetsNoncurrent

1719000000

USD

CY2020Q4

us-gaap

Other Assets Noncurrent

OtherAssetsNoncurrent

1438000000

USD

CY2021Q4

us-gaap

Assets

97460000000

USD

CY2020Q4

us-gaap

Assets

86615000000

USD

CY2021Q4

us-gaap

Liability For Claims And Claims Adjustment Expense

LiabilityForClaimsAndClaimsAdjustmentExpense

13518000000

USD

CY2020Q4

us-gaap

Liability For Claims And Claims Adjustment Expense

LiabilityForClaimsAndClaimsAdjustmentExpense

11359000000

USD

CY2021Q4

us-gaap

Other Policyholder Funds

OtherPolicyholderFunds

5521000000

USD

CY2020Q4

us-gaap

Other Policyholder Funds

OtherPolicyholderFunds

4590000000

USD

CY2021Q4

us-gaap

Unearned Premiums

UnearnedPremiums

1153000000

USD

CY2020Q4

us-gaap

Unearned Premiums

UnearnedPremiums

1259000000

USD

CY2021Q4

us-gaap

Accounts Payable And Accrued Liabilities Current

AccountsPayableAndAccruedLiabilitiesCurrent

4970000000

USD

CY2020Q4

us-gaap

Accounts Payable And Accrued Liabilities Current

AccountsPayableAndAccruedLiabilitiesCurrent

5493000000

USD

CY2021Q4

us-gaap

Short Term Borrowings

ShortTermBorrowings

275000000

USD

CY2020Q4

us-gaap

Short Term Borrowings

ShortTermBorrowings

0

USD

CY2021Q4

us-gaap

Long Term Debt Current

LongTermDebtCurrent

1599000000

USD

CY2020Q4

us-gaap

Long Term Debt Current

LongTermDebtCurrent

700000000

USD

CY2021Q4

us-gaap

Other Liabilities Current

OtherLiabilitiesCurrent

7849000000

USD

CY2020Q4

us-gaap

Other Liabilities Current

OtherLiabilitiesCurrent

6052000000

USD

CY2021Q4

us-gaap

Liabilities Current

LiabilitiesCurrent

34885000000

USD

CY2020Q4

us-gaap

Liabilities Current

LiabilitiesCurrent

29453000000

USD

CY2021Q4

us-gaap

Long Term Debt Noncurrent

LongTermDebtNoncurrent

21157000000

USD

CY2020Q4

us-gaap

Long Term Debt Noncurrent

LongTermDebtNoncurrent

19335000000

USD

CY2021Q4

us-gaap

Liability For Future Policy Benefits

LiabilityForFuturePolicyBenefits

802000000

USD

CY2020Q4

us-gaap

Liability For Future Policy Benefits

LiabilityForFuturePolicyBenefits

794000000

USD

CY2021Q4

us-gaap

Deferred Income Tax Liabilities Net

DeferredIncomeTaxLiabilitiesNet

2805000000

USD

CY2020Q4

us-gaap

Deferred Income Tax Liabilities Net

DeferredIncomeTaxLiabilitiesNet

2019000000

USD

CY2021Q4

us-gaap

Other Liabilities Noncurrent

OtherLiabilitiesNoncurrent

1683000000

USD

CY2020Q4

us-gaap

Other Liabilities Noncurrent

OtherLiabilitiesNoncurrent

1815000000

USD

CY2021Q4

us-gaap

Liabilities

61332000000

USD

CY2020Q4

us-gaap

Liabilities

53416000000

USD

CY2021Q4

us-gaap

Commitments And Contingencies

CommitmentsAndContingencies

USD

CY2020Q4

us-gaap

Commitments And Contingencies

CommitmentsAndContingencies

USD

CY2021Q4

us-gaap

Preferred Stock Shares Authorized

PreferredStockSharesAuthorized

100000000

shares

CY2021Q4

us-gaap

Preferred Stock Shares Outstanding

PreferredStockSharesOutstanding

0

shares

CY2021Q4

us-gaap

Preferred Stock Value

PreferredStockValue

0

USD

CY2020Q4

us-gaap

Preferred Stock Value

PreferredStockValue

0

USD

CY2021Q4

us-gaap

Common Stock Par Or Stated Value Per Share

CommonStockParOrStatedValuePerShare

0.01

CY2021Q4

us-gaap

Common Stock Shares Authorized

CommonStockSharesAuthorized

900000000

shares

CY2021Q4

us-gaap

Common Stock Shares Outstanding

CommonStockSharesOutstanding

241770746

shares

CY2020Q4

us-gaap

Common Stock Shares Outstanding

CommonStockSharesOutstanding

245401430

shares

CY2021Q4

us-gaap

Common Stock Value

CommonStockValue

2000000

USD

CY2020Q4

us-gaap

Common Stock Value

CommonStockValue

3000000

USD

CY2021Q4

us-gaap

Additional Paid In Capital

AdditionalPaidInCapital

9148000000

USD

CY2020Q4

us-gaap

Additional Paid In Capital

AdditionalPaidInCapital

9244000000

USD

CY2021Q4

us-gaap

Retained Earnings Accumulated Deficit

RetainedEarningsAccumulatedDeficit

27088000000

USD

CY2020Q4

us-gaap

Retained Earnings Accumulated Deficit

RetainedEarningsAccumulatedDeficit

23802000000

USD

CY2021Q4

us-gaap

Accumulated Other Comprehensive Income Loss Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNetOfTax

-178000000

USD

CY2020Q4

us-gaap

Accumulated Other Comprehensive Income Loss Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNetOfTax

150000000

USD

CY2021Q4

us-gaap

Stockholders Equity

StockholdersEquity

36060000000

USD

CY2020Q4

us-gaap

Stockholders Equity

StockholdersEquity

33199000000

USD

CY2021Q4

us-gaap

Minority Interest

MinorityInterest

68000000

USD

CY2020Q4

us-gaap

Minority Interest

MinorityInterest

0

USD

CY2021Q4

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

36128000000

USD

CY2020Q4

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

33199000000

USD

CY2021Q4

us-gaap

Liabilities And Stockholders Equity

LiabilitiesAndStockholdersEquity

97460000000

USD

CY2020Q4

us-gaap

Liabilities And Stockholders Equity

LiabilitiesAndStockholdersEquity

86615000000

USD

CY2021

us-gaap

Premiums Earned Net

PremiumsEarnedNet

117373000000

USD

CY2020

us-gaap

Premiums Earned Net

PremiumsEarnedNet

104109000000

USD

CY2019

us-gaap

Premiums Earned Net

PremiumsEarnedNet

94173000000

USD

CY2021

antm

Product Revenue

ProductRevenue

12657000000

USD

CY2020

antm

Product Revenue

ProductRevenue

10384000000

USD

CY2019

antm

Product Revenue

ProductRevenue

2760000000

USD

CY2021

us-gaap

Other Income

OtherIncome

6913000000

USD

CY2020

us-gaap

Other Income

OtherIncome

6315000000

USD

CY2019

us-gaap

Other Income

OtherIncome

6208000000

USD

CY2021

antm

Operating Revenue

OperatingRevenue

136943000000

USD

CY2020

antm

Operating Revenue

OperatingRevenue

120808000000

USD

CY2019

antm

Operating Revenue

OperatingRevenue

103141000000

USD

CY2021

us-gaap

Net Investment Income

NetInvestmentIncome

1378000000

USD

CY2020

us-gaap

Net Investment Income

NetInvestmentIncome

877000000

USD

CY2019

us-gaap

Net Investment Income

NetInvestmentIncome

1005000000

USD

CY2021

antm

Net Gains Losses On Financial Instruments

NetGainsLossesOnFinancialInstruments

318000000

USD

CY2020

antm

Net Gains Losses On Financial Instruments

NetGainsLossesOnFinancialInstruments

182000000

USD

CY2019

antm

Net Gains Losses On Financial Instruments

NetGainsLossesOnFinancialInstruments

67000000

USD

CY2021

us-gaap

Revenues

138639000000

USD

CY2020

us-gaap

Revenues

121867000000

USD

CY2019

us-gaap

Revenues

104213000000

USD

CY2021

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

102645000000

USD

CY2020

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

88045000000

USD

CY2019

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

81786000000

USD

CY2021

us-gaap

Cost Of Goods And Services Sold

CostOfGoodsAndServicesSold

10895000000

USD

CY2020

us-gaap

Cost Of Goods And Services Sold

CostOfGoodsAndServicesSold

8953000000

USD

CY2019

us-gaap

Cost Of Goods And Services Sold

CostOfGoodsAndServicesSold

1992000000

USD

CY2021

us-gaap

Selling General And Administrative Expense

SellingGeneralAndAdministrativeExpense

15914000000

USD

CY2020

us-gaap

Selling General And Administrative Expense

SellingGeneralAndAdministrativeExpense

17450000000

USD

CY2019

us-gaap

Selling General And Administrative Expense

SellingGeneralAndAdministrativeExpense

13364000000

USD

CY2021

us-gaap

Interest Expense

InterestExpense

798000000

USD

CY2020

us-gaap

Interest Expense

InterestExpense

784000000

USD

CY2019

us-gaap

Interest Expense

InterestExpense

746000000

USD

CY2021

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

441000000

USD

CY2020

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

361000000

USD

CY2019

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

338000000

USD

CY2021

us-gaap

Gains Losses On Extinguishment Of Debt

GainsLossesOnExtinguishmentOfDebt

-21000000

USD

CY2020

us-gaap

Gains Losses On Extinguishment Of Debt

GainsLossesOnExtinguishmentOfDebt

-36000000

USD

CY2019

us-gaap

Gains Losses On Extinguishment Of Debt

GainsLossesOnExtinguishmentOfDebt

-2000000

USD

CY2021

us-gaap

Benefits Losses And Expenses

BenefitsLossesAndExpenses

130714000000

USD

CY2020

us-gaap

Benefits Losses And Expenses

BenefitsLossesAndExpenses

115629000000

USD

CY2019

us-gaap

Benefits Losses And Expenses

BenefitsLossesAndExpenses

98228000000

USD

CY2021

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

7925000000

USD

CY2020

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

6238000000

USD

CY2019

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

5985000000

USD

CY2021

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1830000000

USD

CY2020

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1666000000

USD

CY2019

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1178000000

USD

CY2021

us-gaap

Profit Loss

ProfitLoss

6095000000

USD

CY2020

us-gaap

Profit Loss

ProfitLoss

4572000000

USD

CY2019

us-gaap

Profit Loss

ProfitLoss

4807000000

USD

CY2021

us-gaap

Net Income Loss Attributable To Noncontrolling Interest

NetIncomeLossAttributableToNoncontrollingInterest

-9000000

USD

CY2020

us-gaap

Net Income Loss Attributable To Noncontrolling Interest

NetIncomeLossAttributableToNoncontrollingInterest

0

USD

CY2019

us-gaap

Net Income Loss Attributable To Noncontrolling Interest

NetIncomeLossAttributableToNoncontrollingInterest

0

USD

CY2021

us-gaap

Net Income Loss

NetIncomeLoss

6104000000

USD

CY2020

us-gaap

Net Income Loss

NetIncomeLoss

4572000000

USD

CY2019

us-gaap

Net Income Loss

NetIncomeLoss

4807000000

USD

CY2021

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

25.04

CY2020

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

18.23

CY2019

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

18.81

CY2021

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

24.73

CY2020

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

17.98

CY2019

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

18.47

CY2021

us-gaap

Common Stock Dividends Per Share Declared

CommonStockDividendsPerShareDeclared

4.52

CY2020

us-gaap

Common Stock Dividends Per Share Declared

CommonStockDividendsPerShareDeclared

3.80

CY2019

us-gaap

Common Stock Dividends Per Share Declared

CommonStockDividendsPerShareDeclared

3.20

CY2021

us-gaap

Profit Loss

ProfitLoss

6095000000

USD

CY2020

us-gaap

Profit Loss

ProfitLoss

4572000000

USD

CY2019

us-gaap

Profit Loss

ProfitLoss

4807000000

USD

CY2021

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

-457000000

USD

CY2020

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

428000000

USD

CY2019

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

680000000

USD

CY2021

us-gaap

Other Than Temporary Impairment Losses Investments Portion In Other Comprehensive Income Loss Net Of Tax Including Portion Attributable To Noncontrolling Interest Availableforsale Securities

OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities

2000000

USD

CY2020

us-gaap

Other Than Temporary Impairment Losses Investments Portion In Other Comprehensive Income Loss Net Of Tax Including Portion Attributable To Noncontrolling Interest Availableforsale Securities

OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities

0

USD

CY2019

us-gaap

Other Than Temporary Impairment Losses Investments Portion In Other Comprehensive Income Loss Net Of Tax Including Portion Attributable To Noncontrolling Interest Availableforsale Securities

OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities

0

USD

CY2021

us-gaap

Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax

OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax

11000000

USD

CY2020

us-gaap

Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax

OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax

12000000

USD

CY2019

us-gaap

Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax

OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax

-16000000

USD

CY2021

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax

-123000000

USD

CY2020

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax

1000000

USD

CY2019

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax

-26000000

USD

CY2021

us-gaap

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

-9000000

USD

CY2020

us-gaap

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

7000000

USD

CY2019

us-gaap

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

0

USD

CY2021

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

-330000000

USD

CY2020

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

446000000

USD

CY2019

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

690000000

USD

CY2021

us-gaap

Net Income Loss Attributable To Noncontrolling Interest

NetIncomeLossAttributableToNoncontrollingInterest

-9000000

USD

CY2020

us-gaap

Net Income Loss Attributable To Noncontrolling Interest

NetIncomeLossAttributableToNoncontrollingInterest

0

USD

CY2019

us-gaap

Net Income Loss Attributable To Noncontrolling Interest

NetIncomeLossAttributableToNoncontrollingInterest

0

USD

CY2021

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest

-2000000

USD

CY2020

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest

0

USD

CY2019

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest

0

USD

CY2021

us-gaap

Comprehensive Income Net Of Tax

ComprehensiveIncomeNetOfTax

5776000000

USD

CY2020

us-gaap

Comprehensive Income Net Of Tax

ComprehensiveIncomeNetOfTax

5018000000

USD

CY2019

us-gaap

Comprehensive Income Net Of Tax

ComprehensiveIncomeNetOfTax

5497000000

USD

CY2021

us-gaap

Profit Loss

ProfitLoss

6095000000

USD

CY2020

us-gaap

Profit Loss

ProfitLoss

4572000000

USD

CY2019

us-gaap

Profit Loss

ProfitLoss

4807000000

USD

CY2021

antm

Net Gains Losses On Financial Instruments

NetGainsLossesOnFinancialInstruments

318000000

USD

CY2020

antm

Net Gains Losses On Financial Instruments

NetGainsLossesOnFinancialInstruments

182000000

USD

CY2019

antm

Net Gains Losses On Financial Instruments

NetGainsLossesOnFinancialInstruments

67000000

USD

CY2021

us-gaap

Income Loss From Equity Method Investments

IncomeLossFromEquityMethodInvestments

562000000

USD

CY2020

us-gaap

Income Loss From Equity Method Investments

IncomeLossFromEquityMethodInvestments

51000000

USD

CY2019

us-gaap

Income Loss From Equity Method Investments

IncomeLossFromEquityMethodInvestments

93000000

USD

CY2021

us-gaap

Depreciation Amortization And Accretion Net

DepreciationAmortizationAndAccretionNet

1302000000

USD

CY2020

us-gaap

Depreciation Amortization And Accretion Net

DepreciationAmortizationAndAccretionNet

1154000000

USD

CY2019

us-gaap

Depreciation Amortization And Accretion Net

DepreciationAmortizationAndAccretionNet

1133000000

USD

CY2021

us-gaap

Deferred Income Tax Expense Benefit

DeferredIncomeTaxExpenseBenefit

326000000

USD

CY2020

us-gaap

Deferred Income Tax Expense Benefit

DeferredIncomeTaxExpenseBenefit

-540000000

USD

CY2019

us-gaap

Deferred Income Tax Expense Benefit

DeferredIncomeTaxExpenseBenefit

81000000

USD

CY2021

us-gaap

Impairment Of Long Lived Assets Held For Use

ImpairmentOfLongLivedAssetsHeldForUse

73000000

USD

CY2020

us-gaap

Impairment Of Long Lived Assets Held For Use

ImpairmentOfLongLivedAssetsHeldForUse

198000000

USD

CY2019

us-gaap

Impairment Of Long Lived Assets Held For Use

ImpairmentOfLongLivedAssetsHeldForUse

0

USD

CY2021

us-gaap

Share Based Compensation

ShareBasedCompensation

255000000

USD

CY2020

us-gaap

Share Based Compensation

ShareBasedCompensation

283000000

USD

CY2019

us-gaap

Share Based Compensation

ShareBasedCompensation

294000000

USD

CY2021

us-gaap

Increase Decrease In Receivables

IncreaseDecreaseInReceivables

2138000000

USD

CY2020

us-gaap

Increase Decrease In Receivables

IncreaseDecreaseInReceivables

256000000

USD

CY2019

us-gaap

Increase Decrease In Receivables

IncreaseDecreaseInReceivables

1053000000

USD

CY2021

us-gaap

Increase Decrease In Trading Securities

IncreaseDecreaseInTradingSecurities

70000000

USD

CY2020

us-gaap

Increase Decrease In Trading Securities

IncreaseDecreaseInTradingSecurities

32000000

USD

CY2019

us-gaap

Increase Decrease In Trading Securities

IncreaseDecreaseInTradingSecurities

48000000

USD

CY2021

us-gaap

Increase Decrease In Other Operating Assets

IncreaseDecreaseInOtherOperatingAssets

-37000000

USD

CY2020

us-gaap

Increase Decrease In Other Operating Assets

IncreaseDecreaseInOtherOperatingAssets

283000000

USD

CY2019

us-gaap

Increase Decrease In Other Operating Assets

IncreaseDecreaseInOtherOperatingAssets

170000000

USD

CY2021

us-gaap

Increase Decrease In Insurance Liabilities

IncreaseDecreaseInInsuranceLiabilities

2597000000

USD

CY2020

us-gaap

Increase Decrease In Insurance Liabilities

IncreaseDecreaseInInsuranceLiabilities

3528000000

USD

CY2019

us-gaap

Increase Decrease In Insurance Liabilities

IncreaseDecreaseInInsuranceLiabilities

1826000000

USD

CY2021

us-gaap

Increase Decrease In Deferred Revenue

IncreaseDecreaseInDeferredRevenue

-113000000

USD

CY2019

us-gaap

Payments To Acquire Investments

PaymentsToAcquireInvestments

22954000000

USD

CY2020

us-gaap

Increase Decrease In Deferred Revenue

IncreaseDecreaseInDeferredRevenue

202000000

USD

CY2019

us-gaap

Increase Decrease In Deferred Revenue

IncreaseDecreaseInDeferredRevenue

115000000

USD

CY2021

us-gaap

Increase Decrease In Accounts Payable And Other Operating Liabilities

IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities

719000000

USD

CY2020

us-gaap

Increase Decrease In Accounts Payable And Other Operating Liabilities

IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities

1978000000

USD

CY2019

us-gaap

Increase Decrease In Accounts Payable And Other Operating Liabilities

IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities

-445000000

USD

CY2021

us-gaap

Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable

IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable

140000000

USD

CY2020

us-gaap

Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable

IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable

72000000

USD

CY2019

us-gaap

Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable

IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable

-325000000

USD

CY2021

us-gaap

Increase Decrease In Other Operating Capital Net

IncreaseDecreaseInOtherOperatingCapitalNet

-21000000

USD

CY2020

us-gaap

Increase Decrease In Other Operating Capital Net

IncreaseDecreaseInOtherOperatingCapitalNet

-45000000

USD

CY2019

us-gaap

Increase Decrease In Other Operating Capital Net

IncreaseDecreaseInOtherOperatingCapitalNet

-6000000

USD

CY2021

us-gaap

Net Cash Provided By Used In Operating Activities

NetCashProvidedByUsedInOperatingActivities

8364000000

USD

CY2020

us-gaap

Net Cash Provided By Used In Operating Activities

NetCashProvidedByUsedInOperatingActivities

10688000000

USD

CY2019

us-gaap

Net Cash Provided By Used In Operating Activities

NetCashProvidedByUsedInOperatingActivities

6061000000

USD

CY2021

us-gaap

Payments To Acquire Investments

PaymentsToAcquireInvestments

18669000000

USD

CY2020

us-gaap

Payments To Acquire Investments

PaymentsToAcquireInvestments

19492000000

USD

CY2021

antm

Proceedsfromsaleofequityandfixedmaturitysecurities

10269000000

USD

CY2020

antm

Proceedsfromsaleofequityandfixedmaturitysecurities

11318000000

USD

CY2019

antm

Proceedsfromsaleofequityandfixedmaturitysecurities

18598000000

USD

CY2021

us-gaap

Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities

ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities

4344000000

USD

CY2020

us-gaap

Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities

ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities

4741000000

USD

CY2019

us-gaap

Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities

ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities

2437000000

USD

CY2021

us-gaap

Increase Decrease In Collateral Held Under Securities Lending

IncreaseDecreaseInCollateralHeldUnderSecuritiesLending

956000000

USD

CY2020

us-gaap

Increase Decrease In Collateral Held Under Securities Lending

IncreaseDecreaseInCollateralHeldUnderSecuritiesLending

849000000

USD

CY2019

us-gaap

Increase Decrease In Collateral Held Under Securities Lending

IncreaseDecreaseInCollateralHeldUnderSecuritiesLending

-254000000

USD

CY2021

us-gaap

Payments To Acquire Businesses Net Of Cash Acquired

PaymentsToAcquireBusinessesNetOfCashAcquired

3476000000

USD

CY2020

us-gaap

Payments To Acquire Businesses Net Of Cash Acquired

PaymentsToAcquireBusinessesNetOfCashAcquired

1976000000

USD

CY2019

us-gaap

Payments To Acquire Businesses Net Of Cash Acquired

PaymentsToAcquireBusinessesNetOfCashAcquired

0

USD

CY2021

us-gaap

Payments To Acquire Property Plant And Equipment

PaymentsToAcquirePropertyPlantAndEquipment

1087000000

USD

CY2020

us-gaap

Payments To Acquire Property Plant And Equipment

PaymentsToAcquirePropertyPlantAndEquipment

1021000000

USD

CY2019

us-gaap

Payments To Acquire Property Plant And Equipment

PaymentsToAcquirePropertyPlantAndEquipment

1077000000

USD

CY2021

us-gaap

Payments For Proceeds From Other Investing Activities

PaymentsForProceedsFromOtherInvestingActivities

63000000

USD

CY2020

us-gaap

Payments For Proceeds From Other Investing Activities

PaymentsForProceedsFromOtherInvestingActivities

45000000

USD

CY2019

us-gaap

Payments For Proceeds From Other Investing Activities

PaymentsForProceedsFromOtherInvestingActivities

50000000

USD

CY2021

us-gaap

Net Cash Provided By Used In Investing Activities

NetCashProvidedByUsedInInvestingActivities

-9638000000

USD

CY2020

us-gaap

Net Cash Provided By Used In Investing Activities

NetCashProvidedByUsedInInvestingActivities

-7324000000

USD

CY2019

us-gaap

Net Cash Provided By Used In Investing Activities

NetCashProvidedByUsedInInvestingActivities

-2792000000

USD

CY2021

us-gaap

Proceeds From Repayments Of Commercial Paper

ProceedsFromRepaymentsOfCommercialPaper

50000000

USD

CY2020

us-gaap

Proceeds From Repayments Of Commercial Paper

ProceedsFromRepaymentsOfCommercialPaper

-150000000

USD

CY2019

us-gaap

Proceeds From Repayments Of Commercial Paper

ProceedsFromRepaymentsOfCommercialPaper

-297000000

USD

CY2021

us-gaap

Proceeds From Issuance Of Long Term Debt

ProceedsFromIssuanceOfLongTermDebt

3462000000

USD

CY2020

us-gaap

Proceeds From Issuance Of Long Term Debt

ProceedsFromIssuanceOfLongTermDebt

2484000000

USD

CY2019

us-gaap

Proceeds From Issuance Of Long Term Debt

ProceedsFromIssuanceOfLongTermDebt

2473000000

USD

CY2021

us-gaap

Repayments Of Long Term Debt

RepaymentsOfLongTermDebt

1068000000

USD

CY2020

us-gaap

Repayments Of Long Term Debt

RepaymentsOfLongTermDebt

1932000000

USD

CY2019

us-gaap

Repayments Of Long Term Debt

RepaymentsOfLongTermDebt

1123000000

USD

CY2021

us-gaap

Proceeds From Short Term Debt

ProceedsFromShortTermDebt

1325000000

USD

CY2020

us-gaap

Proceeds From Short Term Debt

ProceedsFromShortTermDebt

970000000

USD

CY2019

us-gaap

Proceeds From Short Term Debt

ProceedsFromShortTermDebt

7590000000

USD

CY2021

us-gaap

Repayments Of Short Term Debt

RepaymentsOfShortTermDebt

1050000000

USD

CY2020

us-gaap

Repayments Of Short Term Debt

RepaymentsOfShortTermDebt

1670000000

USD

CY2019

us-gaap

Repayments Of Short Term Debt

RepaymentsOfShortTermDebt

8035000000

USD

CY2021

us-gaap

Increase Decrease In Securities Lending Payable

IncreaseDecreaseInSecuritiesLendingPayable

956000000

USD

CY2020

us-gaap

Increase Decrease In Securities Lending Payable

IncreaseDecreaseInSecuritiesLendingPayable

849000000

USD

CY2019

us-gaap

Increase Decrease In Securities Lending Payable

IncreaseDecreaseInSecuritiesLendingPayable

-254000000

USD

CY2021

us-gaap

Payments For Repurchase Of Common Stock

PaymentsForRepurchaseOfCommonStock

1900000000

USD

CY2020

us-gaap

Payments For Repurchase Of Common Stock

PaymentsForRepurchaseOfCommonStock

2700000000

USD

CY2019

us-gaap

Payments For Repurchase Of Common Stock

PaymentsForRepurchaseOfCommonStock

1701000000

USD

CY2021

us-gaap

Payments Of Dividends

PaymentsOfDividends

1104000000

USD

CY2020

us-gaap

Payments Of Dividends

PaymentsOfDividends

954000000

USD

CY2019

us-gaap

Payments Of Dividends

PaymentsOfDividends

818000000

USD

CY2021

us-gaap

Proceeds From Stock Options Exercised

ProceedsFromStockOptionsExercised

203000000

USD

CY2020

us-gaap

Proceeds From Stock Options Exercised

ProceedsFromStockOptionsExercised

176000000

USD

CY2019

us-gaap

Proceeds From Stock Options Exercised

ProceedsFromStockOptionsExercised

187000000

USD

CY2021

us-gaap

Payments Related To Tax Withholding For Share Based Compensation

PaymentsRelatedToTaxWithholdingForShareBasedCompensation

102000000

USD

CY2020

us-gaap

Payments Related To Tax Withholding For Share Based Compensation

PaymentsRelatedToTaxWithholdingForShareBasedCompensation

128000000

USD

CY2019

us-gaap

Payments Related To Tax Withholding For Share Based Compensation

PaymentsRelatedToTaxWithholdingForShareBasedCompensation

84000000

USD

CY2021

us-gaap

Proceeds From Payments For Other Financing Activities

ProceedsFromPaymentsForOtherFinancingActivities

-349000000

USD

CY2020

us-gaap

Proceeds From Payments For Other Financing Activities

ProceedsFromPaymentsForOtherFinancingActivities

488000000

USD

CY2019

us-gaap

Proceeds From Payments For Other Financing Activities

ProceedsFromPaymentsForOtherFinancingActivities

-204000000

USD

CY2021

us-gaap

Net Cash Provided By Used In Financing Activities

NetCashProvidedByUsedInFinancingActivities

423000000

USD

CY2020

us-gaap

Net Cash Provided By Used In Financing Activities

NetCashProvidedByUsedInFinancingActivities

-2567000000

USD

CY2019

us-gaap

Net Cash Provided By Used In Financing Activities

NetCashProvidedByUsedInFinancingActivities

-2266000000

USD

CY2021

us-gaap

Effect Of Exchange Rate On Cash And Cash Equivalents

EffectOfExchangeRateOnCashAndCashEquivalents

-10000000

USD

CY2020

us-gaap

Effect Of Exchange Rate On Cash And Cash Equivalents

EffectOfExchangeRateOnCashAndCashEquivalents

7000000

USD

CY2019

us-gaap

Effect Of Exchange Rate On Cash And Cash Equivalents

EffectOfExchangeRateOnCashAndCashEquivalents

0

USD

CY2021

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

-861000000

USD

CY2020

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

804000000

USD

CY2019

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

1003000000

USD

CY2020Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

5741000000

USD

CY2019Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

4937000000

USD

CY2018Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

3934000000

USD

CY2021Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

4880000000

USD

CY2020Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

5741000000

USD

CY2019Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

4937000000

USD

CY2018Q4

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

28567000000

USD

CY2019

us-gaap

Profit Loss

ProfitLoss

4807000000

USD

CY2019

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

690000000

USD

CY2019

us-gaap

Stock Repurchased And Retired During Period Value

StockRepurchasedAndRetiredDuringPeriodValue

1701000000

USD

CY2019

us-gaap

Dividends Common Stock

DividendsCommonStock

822000000

USD

CY2019

us-gaap

Stock Issued During Period Value Stock Options Exercised

StockIssuedDuringPeriodValueStockOptionsExercised

396000000

USD

CY2019

us-gaap

Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments

AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments

-209000000

USD

CY2019Q4

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

31728000000

USD

CY2020

us-gaap

Profit Loss

ProfitLoss

4572000000

USD

CY2020

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

446000000

USD

CY2020

us-gaap

Stock Repurchased And Retired During Period Value

StockRepurchasedAndRetiredDuringPeriodValue

2700000000

USD

CY2020

us-gaap

Dividends Common Stock

DividendsCommonStock

961000000

USD

CY2020

us-gaap

Stock Issued During Period Value Stock Options Exercised

StockIssuedDuringPeriodValueStockOptionsExercised

330000000

USD

CY2020

us-gaap

Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments

AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments

-181000000

USD

CY2020Q4

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

33199000000

USD

CY2021

us-gaap

Profit Loss

ProfitLoss

6095000000

USD

CY2021

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

-330000000

USD

CY2021

us-gaap

Minority Interest Period Increase Decrease

MinorityInterestPeriodIncreaseDecrease

79000000

USD

CY2021

us-gaap

Stock Repurchased And Retired During Period Value

StockRepurchasedAndRetiredDuringPeriodValue

1900000000

USD

CY2021

us-gaap

Dividends Common Stock

DividendsCommonStock

1111000000

USD

CY2021

us-gaap

Stock Issued During Period Value Stock Options Exercised

StockIssuedDuringPeriodValueStockOptionsExercised

355000000

USD

CY2021

us-gaap

Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments

AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments

-259000000

USD

CY2021Q4

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

36128000000

USD

CY2021

us-gaap

Nature Of Operations

NatureOfOperations

Organization <div style="margin-bottom:9pt;text-indent:18pt">References to the terms “we,” “our,” “us” or “Anthem” used throughout these Notes to Consolidated Financial Statements refer to Anthem, Inc., an Indiana corporation, and unless the context otherwise requires, its direct and indirect subsidiaries. </div><div style="margin-bottom:9pt;text-indent:18pt">We are one of the largest health benefits companies in the United States in terms of medical membership, serving greater than 45 million medical members through our affiliated health plans as of December 31, 2021. We offer a broad spectrum of network-based managed care risk-based plans to Individual, Group, Medicaid and Medicare markets. In addition, we provide a broad array of managed care services to fee-based customers, including claims processing, stop loss insurance, provider network access, medical management, care management and wellness programs, actuarial services and other administrative services. We also provide services to the federal government in connection with our Federal Health Products & Services business, which administers the Federal Employees Health Benefits (“FEHB”) Program. We provide an array of specialty services both to our subsidiary health plans and also unaffiliated health plans, including pharmacy benefit management (“PBM”) services and dental, vision, life, disability and supplemental health insurance benefits, as well as integrated health services.</div><div style="margin-bottom:12pt;text-indent:18pt">We are an independent licensee of the Blue Cross and Blue Shield Association (“BCBSA”), an association of independent health benefit plans. We serve our members as the Blue Cross licensee for California and as the Blue Cross and Blue Shield (“BCBS”) licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding 30 counties in the Kansas City area), Nevada, New Hampshire, New York (in the New York City metropolitan area and upstate New York), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a majority of these service areas, we do business as Anthem Blue Cross, Anthem Blue Cross and Blue Shield, and Empire Blue Cross Blue Shield or Empire Blue Cross. We also conduct business through arrangements with other BCBS licensees as well as other strategic partners. Through our subsidiaries, we also serve customers in numerous states and Puerto Rico as AIM Specialty Health, Amerigroup, Aspire Health, Beacon, CareMore, Freedom Health, HealthLink, HealthSun, MMM, Optimum HealthCare, Simply Healthcare, and/or UniCare. PBM services are offered through our IngenioRx, Inc. (“IngenioRx”) subsidiary. We are licensed to conduct insurance operations in all 50 states, the District of Columbia and Puerto Rico through our subsidiaries.</div>

CY2021Q4

antm

Number Of Medical Members Served

NumberOfMedicalMembersServed

45000000

individuals

CY2021Q4

antm

Number Of Counties In Geographical Region Not Served

NumberOfCountiesInGeographicalRegionNotServed

30

counties

CY2021Q4

us-gaap

Number Of States In Which Entity Operates

NumberOfStatesInWhichEntityOperates

50

states

CY2021

us-gaap

Prior Period Reclassification Adjustment Description

PriorPeriodReclassificationAdjustmentDescription

Reclassifications: Certain prior year amounts have been reclassified to conform to the current year presentation.

CY2021

us-gaap

Use Of Estimates

UseOfEstimates

Use of Estimates: The preparation of consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Our most significant estimate relates to estimates and judgments for medical claims payable. Actual results could differ from those estimates.

CY2021Q4

us-gaap

Restricted Cash And Investments Current

RestrictedCashAndInvestmentsCurrent

173000000

USD

CY2020Q4

us-gaap

Restricted Cash And Investments Current

RestrictedCashAndInvestmentsCurrent

170000000

USD

CY2021

antm

Securities Lending Transactions Ratioof Fair Valueof Collateral Held To Securities On Loan

SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan

1.02

CY2021Q4

us-gaap

Premiums Receivable Allowance For Doubtful Accounts

PremiumsReceivableAllowanceForDoubtfulAccounts

142000000

USD

CY2020Q4

us-gaap

Premiums Receivable Allowance For Doubtful Accounts

PremiumsReceivableAllowanceForDoubtfulAccounts

146000000

USD

CY2021Q4

antm

Selffunded Receivables Allowance For Doubtful Accounts

SelffundedReceivablesAllowanceForDoubtfulAccounts

50000000

USD

CY2020Q4

antm

Selffunded Receivables Allowance For Doubtful Accounts

SelffundedReceivablesAllowanceForDoubtfulAccounts

54000000

USD

CY2021Q4

us-gaap

Allowance For Doubtful Other Receivables Current

AllowanceForDoubtfulOtherReceivablesCurrent

648000000

USD

CY2020Q4

us-gaap

Allowance For Doubtful Other Receivables Current

AllowanceForDoubtfulOtherReceivablesCurrent

374000000

USD

CY2021

us-gaap

Defined Benefit Plan Alternative Method Used To Amortize Net Gains And Losses

DefinedBenefitPlanAlternativeMethodUsedToAmortizeNetGainsAndLosses

We determine the expected return on plan assets using the calculated value of plan assets, which recognizes changes in the fair value of plan assets in a systematic manner over three years. We apply a corridor approach to amortize unrecognized actuarial gains or losses. Under this approach, only accumulated net actuarial gains or losses in excess of 10% of the greater of the projected benefit obligation or the fair value of plan assets are amortized over the average remaining service or lifetime of the workforce as a component of net periodic benefit cost.

CY2020

us-gaap

Marketing And Advertising Expense

MarketingAndAdvertisingExpense

558000000

USD

CY2019

us-gaap

Marketing And Advertising Expense

MarketingAndAdvertisingExpense

467000000

USD

CY2021

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent

SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent

0.90

CY2021

us-gaap

Marketing And Advertising Expense

MarketingAndAdvertisingExpense

588000000

USD

CY2020Q4

antm

Patient Protection Affordable Care Act Health Insurance Provider Fee

PatientProtectionAffordableCareActHealthInsuranceProviderFee

15523000000

USD

CY2020

antm

Patient Protection Affordable Care Act Health Insurance Provider Fee Amount Paid

PatientProtectionAffordableCareActHealthInsuranceProviderFeeAmountPaid

1570000000

USD

CY2021

us-gaap

Operating Lease Impairment Loss

OperatingLeaseImpairmentLoss

136000000

USD

CY2020

us-gaap

Operating Lease Impairment Loss

OperatingLeaseImpairmentLoss

258000000

USD

CY2021

us-gaap

Payments To Acquire Businesses Gross

PaymentsToAcquireBusinessesGross

4021000000

USD

CY2021

us-gaap

Finitelived Intangible Assets Acquired1

FinitelivedIntangibleAssetsAcquired1

1577000000

USD

CY2021

us-gaap

Indefinitelived Intangible Assets Acquired

IndefinitelivedIntangibleAssetsAcquired

20000000

USD

CY2021

us-gaap

Goodwill Acquired During Period

GoodwillAcquiredDuringPeriod

2521000000

USD

CY2021Q4

us-gaap

Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents

BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents

808000000

USD

CY2020Q4

us-gaap

Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents

BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents

659000000

USD

CY2021Q4

antm

Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Accounts Receivables And Other Current Assets

BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAccountsReceivablesAndOtherCurrentAssets

295000000

USD

CY2020Q4

antm

Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Accounts Receivables And Other Current Assets

BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAccountsReceivablesAndOtherCurrentAssets

282000000

USD

CY2021Q4

antm

Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property And Equipment And Other Long Term Assets

BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyAndEquipmentAndOtherLongTermAssets

102000000

USD

CY2020Q4

antm

Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property And Equipment And Other Long Term Assets

BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyAndEquipmentAndOtherLongTermAssets

296000000

USD

CY2021Q4

antm

Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Medical Claims And Other Policyholder Liabilities

BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMedicalClaimsAndOtherPolicyholderLiabilities

571000000

USD

CY2020Q4

antm

Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Medical Claims And Other Policyholder Liabilities

BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMedicalClaimsAndOtherPolicyholderLiabilities

580000000

USD

CY2021Q4

antm

Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable And Other Current Liabilities

BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherCurrentLiabilities

179000000

USD

CY2020Q4

antm

Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable And Other Current Liabilities

BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherCurrentLiabilities

257000000

USD

CY2021Q4

us-gaap

Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Liabilities Other

BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther

6000000

USD

CY2020Q4

us-gaap

Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Liabilities Other

BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther

49000000

USD

CY2021Q4

us-gaap

Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net

BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet

449000000

USD

CY2020Q4

us-gaap

Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net

BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet

351000000

USD

CY2021Q4

antm

Total Intangible Assets Acquired

TotalIntangibleAssetsAcquired

1597000000

USD

CY2020Q4

antm

Total Intangible Assets Acquired

TotalIntangibleAssetsAcquired

1092000000

USD

CY2021

us-gaap

Restructuring And Related Cost Incurred Cost

RestructuringAndRelatedCostIncurredCost

202000000

USD

CY2020

us-gaap

Restructuring And Related Cost Incurred Cost

RestructuringAndRelatedCostIncurredCost

653000000

USD

CY2021Q4

antm

Equity Securities

EquitySecurities

1881000000

USD

CY2020Q4

antm

Equity Securities

EquitySecurities

1559000000

USD

CY2021

us-gaap

Investment Income Net

InvestmentIncomeNet

1419000000

USD

CY2020

us-gaap

Investment Income Net

InvestmentIncomeNet

915000000

USD

CY2019

us-gaap

Investment Income Net

InvestmentIncomeNet

1034000000

USD

CY2021

us-gaap

Investment Income Investment Expense

InvestmentIncomeInvestmentExpense

41000000

USD

CY2020

us-gaap

Investment Income Investment Expense

InvestmentIncomeInvestmentExpense

38000000

USD

CY2019

us-gaap

Investment Income Investment Expense

InvestmentIncomeInvestmentExpense

29000000

USD

CY2021

us-gaap

Net Investment Income

NetInvestmentIncome

1378000000

USD

CY2020

us-gaap

Net Investment Income

NetInvestmentIncome

877000000

USD

CY2019

us-gaap

Net Investment Income

NetInvestmentIncome

1005000000

USD

CY2021

antm

Investment Gains Losses

InvestmentGainsLosses

311000000

USD

CY2020

antm

Investment Gains Losses

InvestmentGainsLosses

184000000

USD

CY2019

antm

Investment Gains Losses

InvestmentGainsLosses

84000000

USD

CY2021

us-gaap

Equity Securities Fv Ni Gain Loss

EquitySecuritiesFvNiGainLoss

-71000000

USD

CY2020

us-gaap

Equity Securities Fv Ni Gain Loss

EquitySecuritiesFvNiGainLoss

194000000

USD

CY2019

us-gaap

Equity Securities Fv Ni Gain Loss

EquitySecuritiesFvNiGainLoss

63000000

USD

CY2021

us-gaap

Equity Securities Fv Ni Realized Gain Loss

EquitySecuritiesFvNiRealizedGainLoss

-73000000

USD

CY2020

us-gaap

Equity Securities Fv Ni Realized Gain Loss

EquitySecuritiesFvNiRealizedGainLoss

61000000

USD

CY2019

us-gaap

Equity Securities Fv Ni Realized Gain Loss

EquitySecuritiesFvNiRealizedGainLoss

39000000

USD

CY2021

us-gaap

Equity Securities Fv Ni Unrealized Gain Loss

EquitySecuritiesFvNiUnrealizedGainLoss

2000000

USD

CY2020

us-gaap

Equity Securities Fv Ni Unrealized Gain Loss

EquitySecuritiesFvNiUnrealizedGainLoss

133000000

USD

CY2019

us-gaap

Equity Securities Fv Ni Unrealized Gain Loss

EquitySecuritiesFvNiUnrealizedGainLoss

24000000

USD

CY2021Q4

antm

Number Of Fixed Maturity Investments That Did Not Produce Income

NumberOfFixedMaturityInvestmentsThatDidNotProduceIncome

2

CY2020Q4

antm

Number Of Fixed Maturity Investments That Did Not Produce Income

NumberOfFixedMaturityInvestmentsThatDidNotProduceIncome

3

CY2021Q4

us-gaap

Contractual Obligation

ContractualObligation

1558000000

USD

CY2020Q4

us-gaap

Contractual Obligation

ContractualObligation

1320000000

USD

CY2021Q4

us-gaap

Assets Held By Insurance Regulators

AssetsHeldByInsuranceRegulators

632000000

USD

CY2020Q4

us-gaap

Assets Held By Insurance Regulators

AssetsHeldByInsuranceRegulators

562000000

USD

CY2021Q4

us-gaap

Accrued Investment Income Receivable

AccruedInvestmentIncomeReceivable

205000000

USD

CY2020Q4

us-gaap

Accrued Investment Income Receivable

AccruedInvestmentIncomeReceivable

188000000

USD

CY2021Q4

us-gaap

Securities Loaned Fair Value Of Collateral

SecuritiesLoanedFairValueOfCollateral

2155000000

USD

CY2020Q4

us-gaap

Securities Loaned Fair Value Of Collateral

SecuritiesLoanedFairValueOfCollateral

1199000000

USD

CY2021

antm

Securities Lending Transactions Ratioof Fair Valueof Collateral Held To Securities On Loan

SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan

1.02

CY2021Q4

us-gaap

Derivative Asset Collateral Obligation To Return Cash Offset

DerivativeAssetCollateralObligationToReturnCashOffset

18000000

USD

CY2020Q4

us-gaap

Derivative Asset Collateral Obligation To Return Cash Offset

DerivativeAssetCollateralObligationToReturnCashOffset

37000000

USD

CY2021Q4

us-gaap

Derivative Notional Amount

DerivativeNotionalAmount

1407000000

USD

CY2021Q4

us-gaap

Derivative Fair Value Of Derivative Asset

DerivativeFairValueOfDerivativeAsset

47000000

USD

CY2021Q4

us-gaap

Derivative Fair Value Of Derivative Liability

DerivativeFairValueOfDerivativeLiability

29000000

USD

CY2021Q4

us-gaap

Derivative Asset Fair Value Gross Liability

DerivativeAssetFairValueGrossLiability

21000000

USD

CY2021Q4

us-gaap

Derivative Liability Fair Value Gross Asset

DerivativeLiabilityFairValueGrossAsset

21000000

USD

CY2021Q4

us-gaap

Derivative Fair Value Of Derivative Asset Amount Not Offset Against Collateral

DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral

26000000

USD

CY2021Q4

us-gaap

Derivative Fair Value Of Derivative Liability Amount Not Offset Against Collateral

DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral

8000000

USD

CY2020Q4

us-gaap

Derivative Notional Amount

DerivativeNotionalAmount

785000000

USD

CY2020Q4

us-gaap

Derivative Fair Value Of Derivative Asset

DerivativeFairValueOfDerivativeAsset

43000000

USD

CY2020Q4

us-gaap

Derivative Fair Value Of Derivative Liability

DerivativeFairValueOfDerivativeLiability

5000000

USD

CY2020Q4

us-gaap

Derivative Asset Fair Value Gross Liability

DerivativeAssetFairValueGrossLiability

0

USD

CY2020Q4

us-gaap

Derivative Liability Fair Value Gross Asset

DerivativeLiabilityFairValueGrossAsset

0

USD

CY2020Q4

us-gaap

Derivative Fair Value Of Derivative Asset Amount Not Offset Against Collateral

DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral

43000000

USD

CY2020Q4

us-gaap

Derivative Fair Value Of Derivative Liability Amount Not Offset Against Collateral

DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral

5000000

USD

CY2021

us-gaap

Derivative Gain Loss On Derivative Net

DerivativeGainLossOnDerivativeNet

7000000

USD

CY2020

us-gaap

Derivative Gain Loss On Derivative Net

DerivativeGainLossOnDerivativeNet

-2000000

USD

CY2019

us-gaap

Derivative Gain Loss On Derivative Net

DerivativeGainLossOnDerivativeNet

-17000000

USD

CY2021Q4

us-gaap

Cash And Cash Equivalents Fair Value Disclosure

CashAndCashEquivalentsFairValueDisclosure

2415000000

USD

CY2021Q4

us-gaap

Securities Held As Collateral At Fair Value

SecuritiesHeldAsCollateralAtFairValue

2155000000

USD

CY2021Q4

us-gaap

Assets Fair Value Disclosure

AssetsFairValueDisclosure

33507000000

USD

CY2021Q4

us-gaap

Financial Liabilities Fair Value Disclosure

FinancialLiabilitiesFairValueDisclosure

1000000

USD

CY2020Q4

us-gaap

Cash And Cash Equivalents Fair Value Disclosure

CashAndCashEquivalentsFairValueDisclosure

3163000000

USD

CY2020Q4

us-gaap

Securities Held As Collateral At Fair Value

SecuritiesHeldAsCollateralAtFairValue

1199000000

USD

CY2020Q4

us-gaap

Assets Fair Value Disclosure

AssetsFairValueDisclosure

29959000000

USD

CY2020Q4

us-gaap

Financial Liabilities Fair Value Disclosure

FinancialLiabilitiesFairValueDisclosure

5000000

USD

CY2020Q4

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue

392000000

USD

CY2021

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1

19000000

USD

CY2021

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Other Comprehensive Income Loss

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss

3000000

USD

CY2021

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Purchases

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases

216000000

USD

CY2021

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Sales

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales

22000000

USD

CY2021

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Settlements

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements

157000000

USD

CY2021

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3

3000000

USD

CY2021

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3

5000000

USD

CY2021Q4

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue

449000000

USD

CY2021

us-gaap

Fair Value Assets Measured On Recurring Basis Change In Unrealized Gain Loss

FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss

18000000

USD

CY2019Q4

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue

397000000

USD

CY2020

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1

-22000000

USD

CY2020

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Other Comprehensive Income Loss

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss

-5000000

USD

CY2020

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Purchases

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases

101000000

USD

CY2020

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Sales

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales

41000000

USD

CY2020

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Settlements

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements

46000000

USD

CY2020

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3

10000000

USD

CY2020

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3

2000000

USD

CY2020Q4

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue

392000000

USD

CY2020

us-gaap

Fair Value Assets Measured On Recurring Basis Change In Unrealized Gain Loss

FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss

-19000000

USD

CY2018Q4

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue

623000000

USD

CY2019

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1

-13000000

USD

CY2019

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Other Comprehensive Income Loss

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss

3000000

USD

CY2019

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Purchases

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases

189000000

USD

CY2019

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Sales

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales

101000000

USD

CY2019

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Settlements

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements

79000000

USD

CY2019

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3

5000000

USD

CY2019

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3

230000000

USD

CY2019Q4

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue

397000000

USD

CY2019

us-gaap

Fair Value Assets Measured On Recurring Basis Change In Unrealized Gain Loss

FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss

6000000

USD

CY2021Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities

DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities

511000000

USD

CY2020Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities

DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities

588000000

USD

CY2021Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts

DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts

246000000

USD

CY2020Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts

DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts

143000000

USD

CY2021Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Loss Reserves

DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves

156000000

USD

CY2020Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Loss Reserves

DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves

187000000

USD

CY2021Q4

antm

Deferred Tax Assets Leasing Arrangements

DeferredTaxAssetsLeasingArrangements

216000000

USD

CY2021Q4

us-gaap

Deferred Tax Assets Net

DeferredTaxAssetsNet

1530000000

USD

CY2020Q4

us-gaap

Deferred Tax Assets Net

DeferredTaxAssetsNet

1661000000

USD

CY2020Q4

antm

Deferred Tax Assets Leasing Arrangements

DeferredTaxAssetsLeasingArrangements

204000000

USD

CY2021Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Compensation And Benefits

DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits

170000000

USD

CY2020Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Compensation And Benefits

DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits

205000000

USD

CY2021Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation

DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation

35000000

USD

CY2020Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation

DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation

31000000

USD

CY2021Q4

us-gaap

Deferred Tax Assets Operating Loss Carryforwards

DeferredTaxAssetsOperatingLossCarryforwards

201000000

USD

CY2020Q4

us-gaap

Deferred Tax Assets Operating Loss Carryforwards

DeferredTaxAssetsOperatingLossCarryforwards

274000000

USD

CY2021Q4

us-gaap

Deferred Tax Assets Other

DeferredTaxAssetsOther

207000000

USD

CY2020Q4

us-gaap

Deferred Tax Assets Other

DeferredTaxAssetsOther

113000000

USD

CY2021Q4

us-gaap

Deferred Tax Assets Gross

DeferredTaxAssetsGross

1742000000

USD

CY2020Q4

us-gaap

Deferred Tax Assets Gross

DeferredTaxAssetsGross

1745000000

USD

CY2021Q4

us-gaap

Deferred Tax Assets Valuation Allowance

DeferredTaxAssetsValuationAllowance

212000000

USD

CY2020Q4

us-gaap

Deferred Tax Assets Valuation Allowance

DeferredTaxAssetsValuationAllowance

84000000

USD

CY2021Q4

us-gaap

Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets

DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets

2071000000

USD

CY2020Q4

us-gaap

Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets

DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets

2073000000

USD

CY2021Q4

antm

Deferred Tax Liabilities Non Us Intangible Assets

DeferredTaxLiabilitiesNonUSIntangibleAssets

452000000

USD

CY2020Q4

antm

Deferred Tax Liabilities Non Us Intangible Assets

DeferredTaxLiabilitiesNonUSIntangibleAssets

0

USD

CY2021Q4

us-gaap

Deferred Tax Liabilities Deferred Expense Capitalized Software

DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware

777000000

USD

CY2020Q4

us-gaap

Deferred Tax Liabilities Deferred Expense Capitalized Software

DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware

670000000

USD

CY2021Q4

us-gaap

Deferred Tax Liabilities Property Plant And Equipment

DeferredTaxLiabilitiesPropertyPlantAndEquipment

45000000

USD

CY2020Q4

us-gaap

Deferred Tax Liabilities Property Plant And Equipment

DeferredTaxLiabilitiesPropertyPlantAndEquipment

37000000

USD

CY2021Q4

us-gaap

Deferred Tax Liabilities Investments

DeferredTaxLiabilitiesInvestments

295000000

USD

CY2020Q4

us-gaap

Deferred Tax Liabilities Investments

DeferredTaxLiabilitiesInvestments

407000000

USD

CY2021Q4

antm

Deferred Taxliabilities Deferred Expense Retirementbenefits

DeferredTaxliabilitiesDeferredExpenseRetirementbenefits

314000000

USD

CY2020Q4

antm

Deferred Taxliabilities Deferred Expense Retirementbenefits

DeferredTaxliabilitiesDeferredExpenseRetirementbenefits

260000000

USD

CY2021Q4

us-gaap

Deferred Tax Liabilities Leasing Arrangements

DeferredTaxLiabilitiesLeasingArrangements

126000000

USD

CY2020Q4

us-gaap

Deferred Tax Liabilities Leasing Arrangements

DeferredTaxLiabilitiesLeasingArrangements

131000000

USD

CY2021Q4

us-gaap

Deferred Tax Liabilities Prepaid Expenses

DeferredTaxLiabilitiesPrepaidExpenses

152000000

USD

CY2020Q4

us-gaap

Deferred Tax Liabilities Prepaid Expenses

DeferredTaxLiabilitiesPrepaidExpenses

102000000

USD

CY2021Q4

us-gaap

Deferred Income Tax Liabilities

DeferredIncomeTaxLiabilities

4232000000

USD

CY2020Q4

us-gaap

Deferred Income Tax Liabilities

DeferredIncomeTaxLiabilities

3680000000

USD

CY2021Q4

us-gaap

Deferred Tax Liabilities

DeferredTaxLiabilities

2702000000

USD

CY2020Q4

us-gaap

Deferred Tax Liabilities

DeferredTaxLiabilities

2019000000

USD

CY2021Q4

us-gaap

Deferred Tax Liabilities

DeferredTaxLiabilities

2702000000

USD

CY2020Q4

us-gaap

Deferred Tax Liabilities

DeferredTaxLiabilities

2019000000

USD

CY2021

us-gaap

Current Federal Tax Expense Benefit

CurrentFederalTaxExpenseBenefit

1485000000

USD

CY2020

us-gaap

Current Federal Tax Expense Benefit

CurrentFederalTaxExpenseBenefit

1731000000

USD

CY2019

us-gaap

Current Federal Tax Expense Benefit

CurrentFederalTaxExpenseBenefit

1019000000

USD

CY2021

us-gaap

Current State And Local Tax Expense Benefit

CurrentStateAndLocalTaxExpenseBenefit

165000000

USD

CY2020

us-gaap

Current State And Local Tax Expense Benefit

CurrentStateAndLocalTaxExpenseBenefit

461000000

USD

CY2019

us-gaap

Current State And Local Tax Expense Benefit

CurrentStateAndLocalTaxExpenseBenefit

84000000

USD

CY2021

us-gaap

Current Income Tax Expense Benefit

CurrentIncomeTaxExpenseBenefit

1650000000

USD

CY2020

us-gaap

Current Income Tax Expense Benefit

CurrentIncomeTaxExpenseBenefit

2192000000

USD

CY2019

us-gaap

Current Income Tax Expense Benefit

CurrentIncomeTaxExpenseBenefit

1103000000

USD

CY2021

us-gaap

Deferred Other Tax Expense Benefit

DeferredOtherTaxExpenseBenefit

180000000

USD

CY2020

us-gaap

Deferred Other Tax Expense Benefit

DeferredOtherTaxExpenseBenefit

-526000000

USD

CY2019

us-gaap

Deferred Other Tax Expense Benefit

DeferredOtherTaxExpenseBenefit

75000000

USD

CY2021

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1830000000

USD

CY2020

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1666000000

USD

CY2019

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1178000000

USD

CY2021

us-gaap

Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate

IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate

1664000000

USD

CY2021

us-gaap

Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate

EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

0.210

CY2020

us-gaap

Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate

IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate

1310000000

USD

CY2020

us-gaap

Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate

EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

0.210

CY2019

us-gaap

Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate

IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate

1257000000

USD

CY2019

us-gaap

Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate

EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

0.210

CY2021

us-gaap

Income Tax Reconciliation State And Local Income Taxes

IncomeTaxReconciliationStateAndLocalIncomeTaxes

258000000

USD

CY2021

us-gaap

Effective Income Tax Rate Reconciliation State And Local Income Taxes

EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes

0.033

CY2020

us-gaap

Income Tax Reconciliation State And Local Income Taxes

IncomeTaxReconciliationStateAndLocalIncomeTaxes

235000000

USD

CY2020

us-gaap

Effective Income Tax Rate Reconciliation State And Local Income Taxes

EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes

0.038

CY2019

us-gaap

Income Tax Reconciliation State And Local Income Taxes

IncomeTaxReconciliationStateAndLocalIncomeTaxes

138000000

USD

CY2019

us-gaap

Effective Income Tax Rate Reconciliation State And Local Income Taxes

EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes

0.023

CY2021

us-gaap

Income Tax Reconciliation Deductions

IncomeTaxReconciliationDeductions

22000000

USD

CY2021

us-gaap

Effective Income Tax Rate Reconciliation Deductions

EffectiveIncomeTaxRateReconciliationDeductions

0.003

CY2020

us-gaap

Income Tax Reconciliation Deductions

IncomeTaxReconciliationDeductions

22000000

USD

CY2020

us-gaap

Effective Income Tax Rate Reconciliation Deductions

EffectiveIncomeTaxRateReconciliationDeductions

0.004

CY2019

us-gaap

Income Tax Reconciliation Deductions

IncomeTaxReconciliationDeductions

24000000

USD

CY2019

us-gaap

Effective Income Tax Rate Reconciliation Deductions

EffectiveIncomeTaxRateReconciliationDeductions

0.004

CY2021

antm

Effective Income Tax Reconciliation Patient Protection Affordable Care Act Health Insurance Provider Fee

EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee

0

USD

CY2021

antm

Effective Income Tax Reconciliation Patient Protection Affordable Care Act Health Insurance Provider Fee Percent

EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFeePercent

0

CY2020

antm

Effective Income Tax Reconciliation Patient Protection Affordable Care Act Health Insurance Provider Fee

EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee

330000000

USD

CY2020

antm

Effective Income Tax Reconciliation Patient Protection Affordable Care Act Health Insurance Provider Fee Percent

EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFeePercent

0.053

CY2019

antm

Effective Income Tax Reconciliation Patient Protection Affordable Care Act Health Insurance Provider Fee

EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee

0

USD

CY2019

antm

Effective Income Tax Reconciliation Patient Protection Affordable Care Act Health Insurance Provider Fee Percent

EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFeePercent

0

CY2021

us-gaap

Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions

UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions

5000000

USD

CY2021

antm

Effective Income Tax Rate Reconciliation Recent Acquisitions Amount

EffectiveIncomeTaxRateReconciliationRecentAcquisitionsAmount

0

USD

CY2021

antm

Effective Income Tax Rate Reconciliation Recent Acquisitions Percent

EffectiveIncomeTaxRateReconciliationRecentAcquisitionsPercent

0

CY2020

antm

Effective Income Tax Rate Reconciliation Recent Acquisitions Amount

EffectiveIncomeTaxRateReconciliationRecentAcquisitionsAmount

-110000000

USD

CY2020

antm

Effective Income Tax Rate Reconciliation Recent Acquisitions Percent

EffectiveIncomeTaxRateReconciliationRecentAcquisitionsPercent

-0.018

CY2019

antm

Effective Income Tax Rate Reconciliation Recent Acquisitions Amount

EffectiveIncomeTaxRateReconciliationRecentAcquisitionsAmount

0

USD

CY2019

antm

Effective Income Tax Rate Reconciliation Recent Acquisitions Percent

EffectiveIncomeTaxRateReconciliationRecentAcquisitionsPercent

0

CY2021

us-gaap

Income Tax Reconciliation Other Adjustments

IncomeTaxReconciliationOtherAdjustments

-70000000

USD

CY2021

us-gaap

Effective Income Tax Rate Reconciliation Other Adjustments

EffectiveIncomeTaxRateReconciliationOtherAdjustments

-0.009

CY2020

us-gaap

Income Tax Reconciliation Other Adjustments

IncomeTaxReconciliationOtherAdjustments

-77000000

USD

CY2020

us-gaap

Effective Income Tax Rate Reconciliation Other Adjustments

EffectiveIncomeTaxRateReconciliationOtherAdjustments

-0.012

CY2019

us-gaap

Income Tax Reconciliation Other Adjustments

IncomeTaxReconciliationOtherAdjustments

-193000000

USD

CY2019

us-gaap

Effective Income Tax Rate Reconciliation Other Adjustments

EffectiveIncomeTaxRateReconciliationOtherAdjustments

-0.032

CY2021

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1830000000

USD

CY2021

us-gaap

Effective Income Tax Rate Continuing Operations

EffectiveIncomeTaxRateContinuingOperations

0.231

CY2020

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1666000000

USD

CY2020

us-gaap

Effective Income Tax Rate Continuing Operations

EffectiveIncomeTaxRateContinuingOperations

0.267

CY2019

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1178000000

USD

CY2019

us-gaap

Effective Income Tax Rate Continuing Operations

EffectiveIncomeTaxRateContinuingOperations

0.197

CY2021

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1830000000

USD

CY2021

us-gaap

Unusual Or Infrequent Item Earnings Per Share Impact Net

UnusualOrInfrequentItemEarningsPerShareImpactNet

7.41

CY2020

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1666000000

USD

CY2020

us-gaap

Unusual Or Infrequent Item Earnings Per Share Impact Net

UnusualOrInfrequentItemEarningsPerShareImpactNet

6.55

CY2019

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1178000000

USD

CY2019

us-gaap

Unusual Or Infrequent Item Earnings Per Share Impact Net

UnusualOrInfrequentItemEarningsPerShareImpactNet

4.53

CY2020Q4

us-gaap

Unrecognized Tax Benefits

UnrecognizedTaxBenefits

249000000

USD

CY2019Q4

us-gaap

Unrecognized Tax Benefits

UnrecognizedTaxBenefits

146000000

USD

CY2021

us-gaap

Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions

UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions

10000000

USD

CY2020

us-gaap

Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions

UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions

76000000

USD

CY2021

us-gaap

Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions

UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions

17000000

USD

CY2020

us-gaap

Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions

UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions

40000000

USD

CY2020

us-gaap

Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions

UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions

13000000

USD

CY2021Q4

us-gaap

Unrecognized Tax Benefits

UnrecognizedTaxBenefits

271000000

USD

CY2020Q4

us-gaap

Unrecognized Tax Benefits

UnrecognizedTaxBenefits

249000000

USD

CY2021Q4

us-gaap

Unrecognized Tax Benefits That Would Impact Effective Tax Rate

UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate

250000000

USD

CY2020Q4

us-gaap

Unrecognized Tax Benefits That Would Impact Effective Tax Rate

UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate

227000000

USD

CY2021Q4

antm

Unrecognized Tax Benefits That Would Not Impact Effective Tax Rate In Future Periods If Recognized

UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRateInFuturePeriodsIfRecognized

2000000

USD

CY2017

antm

Income Tax Refund Claims Filed

IncomeTaxRefundClaimsFiled

310000000

USD

CY2021

us-gaap

Unrecognized Tax Benefits Income Tax Penalties And Interest Expense

UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense

-9000000

USD

CY2020

us-gaap

Unrecognized Tax Benefits Income Tax Penalties And Interest Expense

UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense

-7000000

USD

CY2019

us-gaap

Unrecognized Tax Benefits Income Tax Penalties And Interest Expense

UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense

11000000

USD

CY2021Q4

us-gaap

Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued

UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued

42000000

USD

CY2020Q4

us-gaap

Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued

UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued

33000000

USD

CY2021Q4

us-gaap

Decrease In Unrecognized Tax Benefits Is Reasonably Possible

DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible

14000000

USD

CY2021Q4

us-gaap

Increase In Unrecognized Tax Benefits Is Reasonably Possible

IncreaseInUnrecognizedTaxBenefitsIsReasonablyPossible

105000000

USD

CY2021Q4

us-gaap

Income Tax Receivable

IncomeTaxReceivable

173000000

USD

CY2020Q4

us-gaap

Income Tax Receivable

IncomeTaxReceivable

262000000

USD

CY2021

us-gaap

Income Taxes Paid

IncomeTaxesPaid

1299000000

USD

CY2020

us-gaap

Income Taxes Paid

IncomeTaxesPaid

1790000000

USD

CY2019

us-gaap

Income Taxes Paid

IncomeTaxesPaid

1403000000

USD

CY2021Q4

us-gaap

Property Plant And Equipment Gross

PropertyPlantAndEquipmentGross

8259000000

USD

CY2020Q4

us-gaap

Property Plant And Equipment Gross

PropertyPlantAndEquipmentGross

7327000000

USD

CY2021Q4

us-gaap

Accumulated Depreciation Depletion And Amortization Property Plant And Equipment

AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

4340000000

USD

CY2020Q4

us-gaap

Accumulated Depreciation Depletion And Amortization Property Plant And Equipment

AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

3844000000

USD

CY2021Q4

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

3919000000

USD

CY2020Q4

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

3483000000

USD

CY2021

us-gaap

Depreciation

136000000

USD

CY2020

us-gaap

Depreciation

176000000

USD

CY2019

us-gaap

Depreciation

147000000

USD

CY2021

antm

Amortization Expense On Software And Leasehold Improvements

AmortizationExpenseOnSoftwareAndLeaseholdImprovements

532000000

USD

CY2020

antm

Amortization Expense On Software And Leasehold Improvements

AmortizationExpenseOnSoftwareAndLeaseholdImprovements

462000000

USD

CY2019

antm

Amortization Expense On Software And Leasehold Improvements

AmortizationExpenseOnSoftwareAndLeaseholdImprovements

528000000

USD

CY2021

us-gaap

Capitalized Computer Software Amortization1

CapitalizedComputerSoftwareAmortization1

485000000

USD

CY2020

us-gaap

Capitalized Computer Software Amortization1

CapitalizedComputerSoftwareAmortization1

412000000

USD

CY2019

us-gaap

Capitalized Computer Software Amortization1

CapitalizedComputerSoftwareAmortization1

450000000

USD

CY2021Q4

us-gaap

Capitalized Computer Software Gross

CapitalizedComputerSoftwareGross

5626000000

USD

CY2020Q4

us-gaap

Capitalized Computer Software Gross

CapitalizedComputerSoftwareGross

4783000000

USD

CY2021

us-gaap

Impairment Of Long Lived Assets To Be Disposed Of

ImpairmentOfLongLivedAssetsToBeDisposedOf

73000000

USD

CY2020

us-gaap

Impairment Of Long Lived Assets To Be Disposed Of

ImpairmentOfLongLivedAssetsToBeDisposedOf

198000000

USD

CY2019Q4

us-gaap

Goodwill

20500000000

USD

CY2020

us-gaap

Goodwill Period Increase Decrease

GoodwillPeriodIncreaseDecrease

1191000000

USD

CY2020Q4

us-gaap

Goodwill

21691000000

USD

CY2021

us-gaap

Goodwill Period Increase Decrease

GoodwillPeriodIncreaseDecrease

2537000000

USD

CY2021Q4

us-gaap

Goodwill

24228000000

USD

CY2021Q4

us-gaap

Goodwill Impaired Accumulated Impairment Loss

GoodwillImpairedAccumulatedImpairmentLoss

0

USD

CY2021Q4

us-gaap

Finite Lived Intangible Assets Gross

FiniteLivedIntangibleAssetsGross

6532000000

USD

CY2021Q4

us-gaap

Finite Lived Intangible Assets Accumulated Amortization

FiniteLivedIntangibleAssetsAccumulatedAmortization

3506000000

USD

CY2021Q4

us-gaap

Finite Lived Intangible Assets Net

FiniteLivedIntangibleAssetsNet

3026000000

USD

CY2020Q4

us-gaap

Finite Lived Intangible Assets Gross

FiniteLivedIntangibleAssetsGross

5947000000

USD

CY2020Q4

us-gaap

Finite Lived Intangible Assets Accumulated Amortization

FiniteLivedIntangibleAssetsAccumulatedAmortization

4057000000

USD

CY2020Q4

us-gaap

Finite Lived Intangible Assets Net

FiniteLivedIntangibleAssetsNet

1890000000

USD

CY2021Q4

us-gaap

Indefinite Lived Intangible Assets Excluding Goodwill

IndefiniteLivedIntangibleAssetsExcludingGoodwill

7589000000

USD

CY2021Q4

us-gaap

Indefinite Lived Intangible Assets Excluding Goodwill

IndefiniteLivedIntangibleAssetsExcludingGoodwill

7589000000

USD

CY2020Q4

us-gaap

Indefinite Lived Intangible Assets Excluding Goodwill

IndefiniteLivedIntangibleAssetsExcludingGoodwill

7515000000

USD

CY2020Q4

us-gaap

Indefinite Lived Intangible Assets Excluding Goodwill

IndefiniteLivedIntangibleAssetsExcludingGoodwill

7515000000

USD

CY2021Q4

us-gaap

Intangible Assets Gross Excluding Goodwill

IntangibleAssetsGrossExcludingGoodwill

14121000000

USD

CY2021Q4

antm

Intangible Assets Accumulated Amortization Excluding Goodwill

IntangibleAssetsAccumulatedAmortizationExcludingGoodwill

3506000000

USD

CY2021Q4

us-gaap

Intangible Assets Net Excluding Goodwill

IntangibleAssetsNetExcludingGoodwill

10615000000

USD

CY2020Q4

us-gaap

Intangible Assets Gross Excluding Goodwill

IntangibleAssetsGrossExcludingGoodwill

13462000000

USD

CY2020Q4

antm

Intangible Assets Accumulated Amortization Excluding Goodwill

IntangibleAssetsAccumulatedAmortizationExcludingGoodwill

4057000000

USD

CY2020Q4

us-gaap

Intangible Assets Net Excluding Goodwill

IntangibleAssetsNetExcludingGoodwill

9405000000

USD

CY2021Q4

us-gaap

Finite Lived Intangible Assets Amortization Expense Next Twelve Months

FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths

483000000

USD

CY2021Q4

us-gaap

Finite Lived Intangible Assets Amortization Expense Year Two

FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo

429000000

USD

CY2021Q4

us-gaap

Finite Lived Intangible Assets Amortization Expense Year Three

FiniteLivedIntangibleAssetsAmortizationExpenseYearThree

369000000

USD

CY2021Q4

us-gaap

Finite Lived Intangible Assets Amortization Expense Year Four

FiniteLivedIntangibleAssetsAmortizationExpenseYearFour

317000000

USD

CY2021Q4

us-gaap

Finite Lived Intangible Assets Amortization Expense Year Five

FiniteLivedIntangibleAssetsAmortizationExpenseYearFive

264000000

USD

CY2021

us-gaap

Defined Benefit Plan Recognized Net Gain Loss Due To Settlements1

DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1

-26000000

USD

CY2020

us-gaap

Defined Benefit Plan Recognized Net Gain Loss Due To Settlements1

DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1

-29000000

USD

CY2019

us-gaap

Defined Benefit Plan Recognized Net Gain Loss Due To Settlements1

DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1

-9000000

USD

CY2021Q4

antm

Defined Benefit Fair Value Due From Brokers

DefinedBenefitFairValueDueFromBrokers

48000000

USD

CY2021Q4

antm

Claims Settlements To Be Paid From Other Benefit Assets

ClaimsSettlementsToBePaidFromOtherBenefitAssets

29000000

USD

CY2020Q4

antm

Defined Benefit Fair Value Due From Brokers

DefinedBenefitFairValueDueFromBrokers

64000000

USD

CY2021

us-gaap

Defined Contribution Plan Cost Recognized

DefinedContributionPlanCostRecognized

241000000

USD

CY2020

us-gaap

Defined Contribution Plan Cost Recognized

DefinedContributionPlanCostRecognized

221000000

USD

CY2019

us-gaap

Defined Contribution Plan Cost Recognized

DefinedContributionPlanCostRecognized

201000000

USD

CY2021

us-gaap

Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense

ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense

<div style="margin-bottom:6pt;text-indent:18pt">A reconciliation of the beginning and ending balances for medical claims payable, by segment (see Note 20, “Segment Information”), for the year ended December 31, 2021 is as follows:</div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.917%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.765%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Commercial & Specialty Business</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Government Business</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Other</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Gross medical claims payable, beginning of year</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3,294 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">7,646 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">195 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">11,135 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Ceded medical claims payable, beginning of year</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(13)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(33)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(46)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net medical claims payable, beginning of year</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,281 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,613 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">195 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11,089 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Business combinations and purchase adjustments</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">375 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">45 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">420 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net incurred medical claims:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Current year</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">28,132 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">70,670 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,638 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100,440 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Prior years redundancies</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(465)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,222)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(16)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,703)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total net incurred medical claims</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27,667 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">69,448 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,622 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">98,737 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net payments attributable to:</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Current year medical claims</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24,502 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">62,233 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,421 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">88,156 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Prior years medical claims</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,612 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,054 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">163 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,829 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total net payments</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27,114 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">68,287 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,584 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">96,985 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net medical claims payable, end of year</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,834 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,149 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">278 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13,261 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Ceded medical claims payable, end of year</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">21 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Gross medical claims payable, end of year</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3,847 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">9,157 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">278 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">13,282 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-indent:18pt">A reconciliation of the beginning and ending balances for medical claims payable, by segment, for the year ended December 31, 2020 is as follows:</div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.917%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.765%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Commercial & Specialty Business</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Government Business</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Other</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Gross medical claims payable, beginning of year</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3,039 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">5,608 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">8,647 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Ceded medical claims payable, beginning of year</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(14)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(19)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(33)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net medical claims payable, beginning of year</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,025 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,589 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,614 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Business combinations and purchase adjustments</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">141 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">198 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">339 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net incurred medical claims:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Current year</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24,894 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">58,912 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,288 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">85,094 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Prior years redundancies</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(375)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(262)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(637)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total net incurred medical claims</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24,519 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">58,650 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,288 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">84,457 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net payments attributable to:</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Current year medical claims</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">21,736 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">51,602 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,291 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">74,629 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Prior years medical claims</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,527 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,165 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,692 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total net payments</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24,263 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">56,767 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,291 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">82,321 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net medical claims payable, end of year</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,281 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,613 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">195 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11,089 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Ceded medical claims payable, end of year</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">33 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">46 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Gross medical claims payable, end of year</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3,294 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">7,646 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">195 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">11,135 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-indent:18pt">A reconciliation of the beginning and ending balances for medical claims payable, by segment, for the year ended December 31, 2019 is as follows:</div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Commercial & Specialty Business</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Government Business</td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Gross medical claims payable, beginning of year</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,586 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">4,680 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">7,266 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Ceded medical claims payable, beginning of year</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(10)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(24)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(34)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net medical claims payable, beginning of year</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,576 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,656 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,232 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net incurred medical claims:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Current year</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">25,942 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">52,753 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">78,695 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Prior years redundancies</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(190)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(310)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(500)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total net incurred medical claims</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">25,752 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">52,443 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">78,195 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net payments attributable to:</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Current year medical claims</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">23,026 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">47,268 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">70,294 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Prior years medical claims</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,277 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,242 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,519 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total net payments</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">25,303 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">51,510 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">76,813 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net medical claims payable, end of year</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,025 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,589 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,614 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Ceded medical claims payable, end of year</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">33 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Gross medical claims payable, end of year</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3,039 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">5,608 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">8,647 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>

CY2020Q4

antm

Short Duration Contract Liability For Claims Adjustment Expense

ShortDurationContractLiabilityForClaimsAdjustmentExpense

11135000000

USD

CY2020Q4

us-gaap

Reinsurance Recoverable For Unpaid Claims And Claims Adjustments

ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments

46000000

USD

CY2020Q4

antm

Shortdurationcontractliabilityforunpaidclaimsandadjustmentexpense Net

ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet

11089000000

USD

CY2021Q4

antm

Liability For Unpaid Claims And Claims Adjustment Expense Purchase Adjustments

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments

420000000

USD

CY2021

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense

100440000000

USD

CY2021

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense

1703000000

USD

CY2021

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1

98737000000

USD

CY2021

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1

88156000000

USD

CY2021

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1

8829000000

USD

CY2021

us-gaap

Payments For Losses And Loss Adjustment Expense

PaymentsForLossesAndLossAdjustmentExpense

96985000000

USD

CY2021Q4

antm

Shortdurationcontractliabilityforunpaidclaimsandadjustmentexpense Net

ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet

13261000000

USD

CY2021Q4

us-gaap

Reinsurance Recoverable For Unpaid Claims And Claims Adjustments

ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments

21000000

USD

CY2021Q4

antm

Short Duration Contract Liability For Claims Adjustment Expense

ShortDurationContractLiabilityForClaimsAdjustmentExpense

13282000000

USD

CY2019Q4

antm

Short Duration Contract Liability For Claims Adjustment Expense

ShortDurationContractLiabilityForClaimsAdjustmentExpense

8647000000

USD

CY2019Q4

us-gaap

Reinsurance Recoverable For Unpaid Claims And Claims Adjustments

ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments

33000000

USD

CY2019Q4

antm

Shortdurationcontractliabilityforunpaidclaimsandadjustmentexpense Net

ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet

8614000000

USD

CY2020Q4

antm

Liability For Unpaid Claims And Claims Adjustment Expense Purchase Adjustments

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments

339000000

USD

CY2020

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense

85094000000

USD

CY2020

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense

637000000

USD

CY2020

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1

84457000000

USD

CY2020

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1

74629000000

USD

CY2020

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1

7692000000

USD

CY2020

us-gaap

Payments For Losses And Loss Adjustment Expense

PaymentsForLossesAndLossAdjustmentExpense

82321000000

USD

CY2020Q4

antm

Shortdurationcontractliabilityforunpaidclaimsandadjustmentexpense Net

ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet

11089000000

USD

CY2020Q4

us-gaap

Reinsurance Recoverable For Unpaid Claims And Claims Adjustments

ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments

46000000

USD

CY2020Q4

antm

Short Duration Contract Liability For Claims Adjustment Expense

ShortDurationContractLiabilityForClaimsAdjustmentExpense

11135000000

USD

CY2018Q4

antm

Short Duration Contract Liability For Claims Adjustment Expense

ShortDurationContractLiabilityForClaimsAdjustmentExpense

7266000000

USD

CY2018Q4

us-gaap

Reinsurance Recoverable For Unpaid Claims And Claims Adjustments

ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments

34000000

USD

CY2018Q4

antm

Shortdurationcontractliabilityforunpaidclaimsandadjustmentexpense Net

ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet

7232000000

USD

CY2019

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense

78695000000

USD

CY2019

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense

500000000

USD

CY2019

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1

78195000000

USD

CY2019

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1

70294000000

USD

CY2019

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1

6519000000

USD

CY2019

us-gaap

Payments For Losses And Loss Adjustment Expense

PaymentsForLossesAndLossAdjustmentExpense

76813000000

USD

CY2019Q4

antm

Shortdurationcontractliabilityforunpaidclaimsandadjustmentexpense Net

ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet

8614000000

USD

CY2019Q4

us-gaap

Reinsurance Recoverable For Unpaid Claims And Claims Adjustments

ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments

33000000

USD

CY2019

antm

Favorable Unfavorable Developments By Changes In Completion Factors Assumptions

FavorableUnfavorableDevelopmentsByChangesInCompletionFactorsAssumptions

175000000

USD

CY2021

antm

Favorable Unfavorable Developments By Changes In Total Assumptions

FavorableUnfavorableDevelopmentsByChangesInTotalAssumptions

1703000000

USD

CY2019Q4

antm

Short Duration Contract Liability For Claims Adjustment Expense

ShortDurationContractLiabilityForClaimsAdjustmentExpense

8647000000

USD

CY2021

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense

1703000000

USD

CY2021

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense

1703000000

USD

CY2021

antm

Favorable Unfavorable Developments By Changes In Trend Factors Assumptions

FavorableUnfavorableDevelopmentsByChangesInTrendFactorsAssumptions

1429000000

USD

CY2020

antm

Favorable Unfavorable Developments By Changes In Trend Factors Assumptions

FavorableUnfavorableDevelopmentsByChangesInTrendFactorsAssumptions

599000000

USD

CY2019

antm

Favorable Unfavorable Developments By Changes In Trend Factors Assumptions

FavorableUnfavorableDevelopmentsByChangesInTrendFactorsAssumptions

325000000

USD

CY2021

antm

Favorable Unfavorable Developments By Changes In Completion Factors Assumptions

FavorableUnfavorableDevelopmentsByChangesInCompletionFactorsAssumptions

274000000

USD

CY2020

antm

Favorable Unfavorable Developments By Changes In Completion Factors Assumptions

FavorableUnfavorableDevelopmentsByChangesInCompletionFactorsAssumptions

38000000

USD

CY2020

antm

Favorable Unfavorable Developments By Changes In Total Assumptions

FavorableUnfavorableDevelopmentsByChangesInTotalAssumptions

637000000

USD

CY2019

antm

Favorable Unfavorable Developments By Changes In Total Assumptions

FavorableUnfavorableDevelopmentsByChangesInTotalAssumptions

500000000

USD

CY2021

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1

98737000000

USD

CY2020

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1

84457000000

USD

CY2019

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1

78195000000

USD

CY2021

antm

Quality Improvement And Other Claims Expense

QualityImprovementAndOtherClaimsExpense

3908000000

USD

CY2020

antm

Quality Improvement And Other Claims Expense

QualityImprovementAndOtherClaimsExpense

3588000000

USD

CY2019

antm

Quality Improvement And Other Claims Expense

QualityImprovementAndOtherClaimsExpense

3591000000

USD

CY2021

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

102645000000

USD

CY2020

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

88045000000

USD

CY2019

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

81786000000

USD

CY2021Q4

us-gaap

Reinsurance Recoverable For Unpaid Claims And Claims Adjustments

ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments

21000000

USD

CY2021Q4

us-gaap

Shortduration Insurance Contracts Liability For Unpaid Claims And Claim Adjustment Expense Other Reconciling Item

ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem

236000000

USD

CY2021Q4

us-gaap

Liability For Claims And Claims Adjustment Expense

LiabilityForClaimsAndClaimsAdjustmentExpense

13518000000

USD

CY2021Q4

us-gaap

Shortduration Insurance Contracts Incurred Claims And Allocated Claim Adjustment Expense Net

ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet

269380000000

USD

CY2021Q4

us-gaap

Shortduration Insurance Contracts Cumulative Paid Claims And Allocated Claim Adjustment Expense Net

ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet

256119000000

USD

CY2021Q4

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Net

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet

13261000000

USD

CY2020Q4

us-gaap

Long Term Debt Noncurrent

LongTermDebtNoncurrent

19335000000

USD

CY2021Q4

us-gaap

Long Term Debt

LongTermDebt

22756000000

USD

CY2020Q4

us-gaap

Long Term Debt

LongTermDebt

20035000000

USD

CY2021Q4

us-gaap

Long Term Debt Current

LongTermDebtCurrent

1599000000

USD

CY2020Q4

us-gaap

Long Term Debt Current

LongTermDebtCurrent

700000000

USD

CY2021Q4

us-gaap

Long Term Debt Noncurrent

LongTermDebtNoncurrent

21157000000

USD

CY2021Q4

us-gaap

Debt Instrument Convertible Carrying Amount Of The Equity Component

DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent

38000000

USD

CY2021Q4

us-gaap

Debt Instrument Face Amount

DebtInstrumentFaceAmount

105000000

USD

CY2021Q4

us-gaap

Debt Instrument Unamortized Discount

DebtInstrumentUnamortizedDiscount

32000000

USD

CY2021Q4

us-gaap

Convertible Debt Noncurrent

ConvertibleDebtNoncurrent

72000000

USD

CY2021

us-gaap

Debt Instrument Convertible Conversion Ratio1

DebtInstrumentConvertibleConversionRatio1

14.2080

CY2021Q4

us-gaap

Debt Instrument Convertible Conversion Price1

DebtInstrumentConvertibleConversionPrice1

70.3829

CY2021

us-gaap

Interest Paid

InterestPaid

822000000

USD

CY2020

us-gaap

Interest Paid

InterestPaid

794000000

USD

CY2019

us-gaap

Interest Paid

InterestPaid

755000000

USD

CY2021Q4

us-gaap

Long Term Debt Maturities Repayments Of Principal In Next Twelve Months

LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths

1899000000

USD

CY2021Q4

us-gaap

Long Term Debt Maturities Repayments Of Principal In Year Two

LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo

1513000000

USD

CY2021Q4

us-gaap

Long Term Debt Maturities Repayments Of Principal In Year Three

LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree

1645000000

USD

CY2021Q4

us-gaap

Long Term Debt Maturities Repayments Of Principal In Year Four

LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour

1253000000

USD

CY2021Q4

us-gaap

Long Term Debt Maturities Repayments Of Principal In Year Five

LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive

745000000

USD

CY2021Q4

us-gaap

Long Term Debt Maturities Repayments Of Principal After Year Five

LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive

15701000000

USD

CY2021Q4

antm

Gross Premium Tax Rate

GrossPremiumTaxRate

0.0235

CY2021

us-gaap

Long Term Purchase Commitment Amount

LongTermPurchaseCommitmentAmount

1051000000

USD

CY2021

us-gaap

Share Based Compensation

ShareBasedCompensation

255000000

USD

CY2020

us-gaap

Share Based Compensation

ShareBasedCompensation

283000000

USD

CY2021Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue

299.65

CY2019

us-gaap

Share Based Compensation

ShareBasedCompensation

294000000

USD

CY2021

us-gaap

Employee Service Share Based Compensation Tax Benefit From Compensation Expense

EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense

65000000

USD

CY2020

us-gaap

Employee Service Share Based Compensation Tax Benefit From Compensation Expense

EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense

74000000

USD

CY2019

us-gaap

Employee Service Share Based Compensation Tax Benefit From Compensation Expense

EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense

78000000

USD

CY2020Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

3100000

shares

CY2020Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

230.00

CY2021

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod

700000

shares

CY2021

us-gaap

Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

315.30

CY2021

us-gaap

Stock Issued During Period Shares Stock Options Exercised

StockIssuedDuringPeriodSharesStockOptionsExercised

700000

shares

CY2021

us-gaap

Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

201.05

CY2021

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod

200000

shares

CY2021

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice

287.81

CY2021Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

2900000

shares

CY2021

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod

100000

shares

CY2021

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue

290.87

CY2021Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

1300000

shares

CY2021

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

0.0144

CY2021Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

255.50

CY2021

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

P6Y9M10D

CY2021Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

599000000

USD

CY2021Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

1500000

shares

CY2021Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

215.40

CY2021

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1

P5Y5M12D

CY2021Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue

364000000

USD

CY2020Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

1300000

shares

CY2020Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue

272.51

CY2021

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

1000000.0

shares

CY2021

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

317.70

CY2021

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod

900000

shares

CY2021

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue

245.48

CY2021Q3

us-gaap

Dividends Payable Date Declared Day Month And Year

DividendsPayableDateDeclaredDayMonthAndYear

2021-07-20

CY2020

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

0.0130

CY2019

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

0.0269

CY2021

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

0.3000

CY2020

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

0.2600

CY2019

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

0.2500

CY2021

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

0.0150

CY2020

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

0.0140

CY2019

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

0.0100

CY2021

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

P5Y6M

CY2020

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

P4Y3M18D

CY2019

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

P4Y4M24D

CY2021

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

79.91

CY2020

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

54.05

CY2019

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

68.66

CY2021

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

317.70

CY2020

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

272.37

CY2019

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

305.88

CY2021Q1

us-gaap

Dividends Payable Date Declared Day Month And Year

DividendsPayableDateDeclaredDayMonthAndYear

2021-01-26

CY2021Q1

us-gaap

Dividends Payable Date Of Record Day Month And Year

DividendsPayableDateOfRecordDayMonthAndYear

2021-03-10

CY2021Q1

us-gaap

Dividend Payable Date To Be Paid Day Month And Year

DividendPayableDateToBePaidDayMonthAndYear

2021-03-25

CY2021Q1

us-gaap

Common Stock Dividends Per Share Cash Paid

CommonStockDividendsPerShareCashPaid

1.13

CY2021Q1

us-gaap

Payments Of Dividends

PaymentsOfDividends

277000000

USD

CY2021Q2

us-gaap

Dividends Payable Date Declared Day Month And Year

DividendsPayableDateDeclaredDayMonthAndYear

2021-04-20

CY2021Q2

us-gaap

Dividends Payable Date Of Record Day Month And Year

DividendsPayableDateOfRecordDayMonthAndYear

2021-06-10

CY2021Q2

us-gaap

Dividend Payable Date To Be Paid Day Month And Year

DividendPayableDateToBePaidDayMonthAndYear

2021-06-25

CY2021Q2

us-gaap

Common Stock Dividends Per Share Cash Paid

CommonStockDividendsPerShareCashPaid

1.13

CY2021Q2

us-gaap

Payments Of Dividends

PaymentsOfDividends

278000000

USD

CY2021Q4

us-gaap

Dividend Payable Date To Be Paid Day Month And Year

DividendPayableDateToBePaidDayMonthAndYear

2021-12-21

CY2021Q3

us-gaap

Dividends Payable Date Of Record Day Month And Year

DividendsPayableDateOfRecordDayMonthAndYear

2021-09-10

CY2021Q3

us-gaap

Dividend Payable Date To Be Paid Day Month And Year

DividendPayableDateToBePaidDayMonthAndYear

2021-09-24

CY2021Q3

us-gaap

Common Stock Dividends Per Share Cash Paid

CommonStockDividendsPerShareCashPaid

1.13

CY2021Q3

us-gaap

Payments Of Dividends

PaymentsOfDividends

276000000

USD

CY2021Q4

us-gaap

Dividends Payable Date Declared Day Month And Year

DividendsPayableDateDeclaredDayMonthAndYear

2021-10-19

CY2021Q4

us-gaap

Dividends Payable Date Of Record Day Month And Year

DividendsPayableDateOfRecordDayMonthAndYear

2021-12-03

CY2021Q4

us-gaap

Common Stock Dividends Per Share Cash Paid

CommonStockDividendsPerShareCashPaid

1.13

CY2021Q4

us-gaap

Payments Of Dividends

PaymentsOfDividends

273000000

USD

CY2020Q1

us-gaap

Dividends Payable Date Declared Day Month And Year

DividendsPayableDateDeclaredDayMonthAndYear

2020-01-28

CY2020Q1

us-gaap

Dividends Payable Date Of Record Day Month And Year

DividendsPayableDateOfRecordDayMonthAndYear

2020-03-16

CY2020Q1

us-gaap

Dividend Payable Date To Be Paid Day Month And Year

DividendPayableDateToBePaidDayMonthAndYear

2020-03-27

CY2020Q1

us-gaap

Common Stock Dividends Per Share Cash Paid

CommonStockDividendsPerShareCashPaid

0.95

CY2020Q1

us-gaap

Payments Of Dividends

PaymentsOfDividends

240000000

USD

CY2020Q2

us-gaap

Dividends Payable Date Declared Day Month And Year

DividendsPayableDateDeclaredDayMonthAndYear

2020-04-28

CY2020Q2

us-gaap

Dividends Payable Date Of Record Day Month And Year

DividendsPayableDateOfRecordDayMonthAndYear

2020-06-10

CY2020Q2

us-gaap

Dividend Payable Date To Be Paid Day Month And Year

DividendPayableDateToBePaidDayMonthAndYear

2020-06-25

CY2020Q2

us-gaap

Common Stock Dividends Per Share Cash Paid

CommonStockDividendsPerShareCashPaid

0.95

CY2020Q2

us-gaap

Payments Of Dividends

PaymentsOfDividends

242000000

USD

CY2020Q3

us-gaap

Dividends Payable Date Declared Day Month And Year

DividendsPayableDateDeclaredDayMonthAndYear

2020-07-28

CY2020Q3

us-gaap

Dividends Payable Date Of Record Day Month And Year

DividendsPayableDateOfRecordDayMonthAndYear

2020-09-10

CY2020Q3

us-gaap

Dividend Payable Date To Be Paid Day Month And Year

DividendPayableDateToBePaidDayMonthAndYear

2020-09-25

CY2020Q3

us-gaap

Common Stock Dividends Per Share Cash Paid

CommonStockDividendsPerShareCashPaid

0.95

CY2020Q3

us-gaap

Payments Of Dividends

PaymentsOfDividends

238000000

USD

CY2020Q4

us-gaap

Dividends Payable Date Declared Day Month And Year

DividendsPayableDateDeclaredDayMonthAndYear

2020-10-27

CY2020Q4

us-gaap

Dividends Payable Date Of Record Day Month And Year

DividendsPayableDateOfRecordDayMonthAndYear

2020-12-07

CY2020Q4

us-gaap

Dividend Payable Date To Be Paid Day Month And Year

DividendPayableDateToBePaidDayMonthAndYear

2020-12-22

CY2020Q4

us-gaap

Common Stock Dividends Per Share Cash Paid

CommonStockDividendsPerShareCashPaid

0.95

CY2020Q4

us-gaap

Payments Of Dividends

PaymentsOfDividends

234000000

USD

CY2021Q1

antm

Increase In Stock Repurchase Program Authorization

IncreaseInStockRepurchaseProgramAuthorization

5000000000

USD

CY2021

us-gaap

Stock Repurchased And Retired During Period Shares

StockRepurchasedAndRetiredDuringPeriodShares

5100000

shares

CY2020

us-gaap

Stock Repurchased And Retired During Period Shares

StockRepurchasedAndRetiredDuringPeriodShares

9400000

shares

CY2021

antm

Stock Repurchased And Retired During Period Average Price

StockRepurchasedAndRetiredDuringPeriodAveragePrice

371.46

CY2020

antm

Stock Repurchased And Retired During Period Average Price

StockRepurchasedAndRetiredDuringPeriodAveragePrice

286.35

CY2021

us-gaap

Stock Repurchased And Retired During Period Value

StockRepurchasedAndRetiredDuringPeriodValue

1900000000

USD

CY2020

us-gaap

Stock Repurchased And Retired During Period Value

StockRepurchasedAndRetiredDuringPeriodValue

2700000000

USD

CY2021Q4

us-gaap

Stock Repurchase Program Remaining Authorized Repurchase Amount1

StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1

4192000000

USD

CY2020Q4

us-gaap

Stock Repurchase Program Remaining Authorized Repurchase Amount1

StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1

1092000000

USD

CY2020Q4

us-gaap

Accumulated Other Comprehensive Income Loss Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNetOfTax

150000000

USD

CY2019Q4

us-gaap

Accumulated Other Comprehensive Income Loss Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNetOfTax

-296000000

USD

CY2018Q4

us-gaap

Accumulated Other Comprehensive Income Loss Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNetOfTax

-986000000

USD

CY2020

us-gaap

Other Comprehensive Income Loss Tax

OtherComprehensiveIncomeLossTax

154000000

USD

CY2021

us-gaap

Other Comprehensive Income Loss Tax

OtherComprehensiveIncomeLossTax

-110000000

USD

CY2019

us-gaap

Other Comprehensive Income Loss Tax

OtherComprehensiveIncomeLossTax

199000000

USD

CY2021

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

-330000000

USD

CY2020

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

446000000

USD

CY2019

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

690000000

USD

CY2021

us-gaap

Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest

OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest

-1000000

USD

CY2020

us-gaap

Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest

OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest

0

USD

CY2019

us-gaap

Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest

OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest

0

USD

CY2021

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest

-2000000

USD

CY2020

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest

0

USD

CY2019

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest

0

USD

CY2021Q4

us-gaap

Accumulated Other Comprehensive Income Loss Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNetOfTax

-178000000

USD

CY2020Q4

us-gaap

Accumulated Other Comprehensive Income Loss Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNetOfTax

150000000

USD

CY2019Q4

us-gaap

Accumulated Other Comprehensive Income Loss Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNetOfTax

-296000000

USD

CY2021

us-gaap

Direct Premiums Earned

DirectPremiumsEarned

113149000000

USD

CY2020

us-gaap

Direct Premiums Earned

DirectPremiumsEarned

100832000000

USD

CY2019

us-gaap

Direct Premiums Earned

DirectPremiumsEarned

91131000000

USD

CY2021

us-gaap

Assumed Premiums Earned

AssumedPremiumsEarned

4298000000

USD

CY2020

us-gaap

Assumed Premiums Earned

AssumedPremiumsEarned

3356000000

USD

CY2019

us-gaap

Assumed Premiums Earned

AssumedPremiumsEarned

3087000000

USD

CY2021

us-gaap

Ceded Premiums Earned

CededPremiumsEarned

74000000

USD

CY2020

us-gaap

Ceded Premiums Earned

CededPremiumsEarned

79000000

USD

CY2019

us-gaap

Ceded Premiums Earned

CededPremiumsEarned

45000000

USD

CY2021

us-gaap

Premiums Earned Net

PremiumsEarnedNet

117373000000

USD

CY2020

us-gaap

Premiums Earned Net

PremiumsEarnedNet

104109000000

USD

CY2019

us-gaap

Premiums Earned Net

PremiumsEarnedNet

94173000000

USD

CY2021

us-gaap

Premiums Percentage Assumed To Net

PremiumsPercentageAssumedToNet

0.037

CY2020

us-gaap

Premiums Percentage Assumed To Net

PremiumsPercentageAssumedToNet

0.032

CY2019

us-gaap

Premiums Percentage Assumed To Net

PremiumsPercentageAssumedToNet

0.033

CY2021

us-gaap

Premiums Earned Net

PremiumsEarnedNet

117373000000

USD

CY2020

us-gaap

Premiums Earned Net

PremiumsEarnedNet

104109000000

USD

CY2019

us-gaap

Premiums Earned Net

PremiumsEarnedNet

94173000000

USD

CY2021

us-gaap

Policyholder Benefits And Claims Incurred Gross

PolicyholderBenefitsAndClaimsIncurredGross

99007000000

USD

CY2020

us-gaap

Policyholder Benefits And Claims Incurred Gross

PolicyholderBenefitsAndClaimsIncurredGross

85168000000

USD

CY2019

us-gaap

Policyholder Benefits And Claims Incurred Gross

PolicyholderBenefitsAndClaimsIncurredGross

79110000000

USD

CY2021

us-gaap

Reinsurance Effect On Claims And Benefits Incurred Amount Assumed

ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed

3719000000

USD

CY2020

us-gaap

Reinsurance Effect On Claims And Benefits Incurred Amount Assumed

ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed

2967000000

USD

CY2019

us-gaap

Reinsurance Effect On Claims And Benefits Incurred Amount Assumed

ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed

2733000000

USD

CY2021

us-gaap

Reinsurance Effect On Claims And Benefits Incurred Amount Ceded

ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded

81000000

USD

CY2020

us-gaap

Reinsurance Effect On Claims And Benefits Incurred Amount Ceded

ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded

90000000

USD

CY2019

us-gaap

Reinsurance Effect On Claims And Benefits Incurred Amount Ceded

ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded

57000000

USD

CY2021

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

102645000000

USD

CY2020

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

88045000000

USD

CY2019

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

81786000000

USD

CY2021Q4

us-gaap

Assumed Liability For Unpaid Claims And Claims Adjustment Expense

AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense

500000000

USD

CY2020Q4

us-gaap

Assumed Liability For Unpaid Claims And Claims Adjustment Expense

AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense

490000000

USD

CY2021

antm

Assumed Unearned Income

AssumedUnearnedIncome

96000000

USD

CY2020

antm

Assumed Unearned Income

AssumedUnearnedIncome

85000000

USD

CY2021Q4

us-gaap

Ceded Premiums Payable

CededPremiumsPayable

14000000

USD

CY2020Q4

us-gaap

Ceded Premiums Payable

CededPremiumsPayable

12000000

USD

CY2021Q4

antm

Assumed Premiums Receivable

AssumedPremiumsReceivable

248000000

USD

CY2020Q4

antm

Assumed Premiums Receivable

AssumedPremiumsReceivable

347000000

USD

CY2021

us-gaap

Operating Lease Cost

OperatingLeaseCost

261000000

USD

CY2020

us-gaap

Operating Lease Cost

OperatingLeaseCost

438000000

USD

CY2019

us-gaap

Operating Lease Cost

OperatingLeaseCost

198000000

USD

CY2021

us-gaap

Short Term Lease Cost

ShortTermLeaseCost

45000000

USD

CY2020

us-gaap

Short Term Lease Cost

ShortTermLeaseCost

50000000

USD

CY2019

us-gaap

Short Term Lease Cost

ShortTermLeaseCost

46000000

USD

CY2021

us-gaap

Sublease Income

SubleaseIncome

4000000

USD

CY2020

us-gaap

Sublease Income

SubleaseIncome

9000000

USD

CY2019

us-gaap

Sublease Income

SubleaseIncome

16000000

USD

CY2021

us-gaap

Lease Cost

LeaseCost

302000000

USD

CY2020

us-gaap

Lease Cost

LeaseCost

479000000

USD

CY2019

us-gaap

Lease Cost

LeaseCost

228000000

USD

CY2021

us-gaap

Operating Lease Impairment Loss

OperatingLeaseImpairmentLoss

136000000

USD

CY2020

us-gaap

Operating Lease Impairment Loss

OperatingLeaseImpairmentLoss

258000000

USD

CY2021

us-gaap

Operating Lease Payments

OperatingLeasePayments

198000000

USD

CY2020

us-gaap

Operating Lease Payments

OperatingLeasePayments

207000000

USD

CY2021

us-gaap

Right Of Use Asset Obtained In Exchange For Operating Lease Liability

RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability

334000000

USD

CY2020

us-gaap

Right Of Use Asset Obtained In Exchange For Operating Lease Liability

RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability

384000000

USD

CY2021Q4

us-gaap

Operating Lease Weighted Average Remaining Lease Term1

OperatingLeaseWeightedAverageRemainingLeaseTerm1

P7Y

CY2020Q4

us-gaap

Operating Lease Weighted Average Remaining Lease Term1

OperatingLeaseWeightedAverageRemainingLeaseTerm1

P7Y

CY2021Q4

us-gaap

Operating Lease Weighted Average Discount Rate Percent

OperatingLeaseWeightedAverageDiscountRatePercent

0.0269

CY2020Q4

us-gaap

Operating Lease Weighted Average Discount Rate Percent

OperatingLeaseWeightedAverageDiscountRatePercent

0.0321

CY2021Q4

us-gaap

Lessee Operating Lease Liability Payments Due Next Twelve Months

LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths

211000000

USD

CY2021Q4

us-gaap

Lessee Operating Lease Liability Payments Due Year Two

LesseeOperatingLeaseLiabilityPaymentsDueYearTwo

193000000

USD

CY2021Q4

us-gaap

Lessee Operating Lease Liability Payments Due Year Three

LesseeOperatingLeaseLiabilityPaymentsDueYearThree

165000000

USD

CY2021Q4

us-gaap

Lessee Operating Lease Liability Payments Due Year Four

LesseeOperatingLeaseLiabilityPaymentsDueYearFour

126000000

USD

CY2021Q4

us-gaap

Lessee Operating Lease Liability Payments Due Year Five

LesseeOperatingLeaseLiabilityPaymentsDueYearFive

90000000

USD

CY2021Q4

us-gaap

Lessee Operating Lease Liability Payments Due After Year Five

LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive

307000000

USD

CY2021Q4

us-gaap

Lessee Operating Lease Liability Payments Due

LesseeOperatingLeaseLiabilityPaymentsDue

1092000000

USD

CY2021Q4

us-gaap

Lessee Operating Lease Liability Undiscounted Excess Amount

LesseeOperatingLeaseLiabilityUndiscountedExcessAmount

95000000

USD

CY2021Q4

us-gaap

Operating Lease Liability

OperatingLeaseLiability

997000000

USD

CY2021

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

243800000

shares

CY2020

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

250800000

shares

CY2019

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

255500000

shares

CY2021

us-gaap

Weighted Average Number Diluted Shares Outstanding Adjustment

WeightedAverageNumberDilutedSharesOutstandingAdjustment

3000000.0

shares

CY2020

us-gaap

Weighted Average Number Diluted Shares Outstanding Adjustment

WeightedAverageNumberDilutedSharesOutstandingAdjustment

3500000

shares

CY2019

us-gaap

Weighted Average Number Diluted Shares Outstanding Adjustment

WeightedAverageNumberDilutedSharesOutstandingAdjustment

4800000

shares

CY2021

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

246800000

shares

CY2020

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

254300000

shares

CY2019

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

260300000

shares

CY2021

us-gaap

Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount

AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

200000

shares

CY2020

us-gaap

Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount

AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

1200000

shares

CY2019

us-gaap

Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount

AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

600000

shares

CY2021

antm

Potentially Dilutive Restricted Stock Units Contingent On Operating Results

PotentiallyDilutiveRestrictedStockUnitsContingentOnOperatingResults

300000

shares

CY2020

antm

Potentially Dilutive Restricted Stock Units Contingent On Operating Results

PotentiallyDilutiveRestrictedStockUnitsContingentOnOperatingResults

300000

shares

CY2019

antm

Potentially Dilutive Restricted Stock Units Contingent On Operating Results

PotentiallyDilutiveRestrictedStockUnitsContingentOnOperatingResults

200000

shares

CY2021

us-gaap

Number Of Reportable Segments

NumberOfReportableSegments

4

segment

CY2021

us-gaap

Insurance Services Revenue

InsuranceServicesRevenue

136943000000

USD

CY2021

us-gaap

Operating Income Loss

OperatingIncomeLoss

7489000000

USD

CY2021

us-gaap

Other Depreciation And Amortization

OtherDepreciationAndAmortization

668000000

USD

CY2020

us-gaap

Insurance Services Revenue

InsuranceServicesRevenue

120808000000

USD

CY2020

us-gaap

Operating Income Loss

OperatingIncomeLoss

6360000000

USD

CY2020

us-gaap

Other Depreciation And Amortization

OtherDepreciationAndAmortization

638000000

USD

CY2020

antm

Net Gains Losses On Financial Instruments

NetGainsLossesOnFinancialInstruments

182000000

USD

CY2019

us-gaap

Insurance Services Revenue

InsuranceServicesRevenue

103141000000

USD

CY2019

us-gaap

Operating Income Loss

OperatingIncomeLoss

5999000000

USD

CY2019

us-gaap

Other Depreciation And Amortization

OtherDepreciationAndAmortization

675000000

USD

CY2021

us-gaap

Insurance Services Revenue

InsuranceServicesRevenue

136943000000

USD

CY2020

us-gaap

Insurance Services Revenue

InsuranceServicesRevenue

120808000000

USD

CY2019

us-gaap

Insurance Services Revenue

InsuranceServicesRevenue

103141000000

USD

CY2021

us-gaap

Insurance Services Revenue

InsuranceServicesRevenue

136943000000

USD

CY2020

us-gaap

Insurance Services Revenue

InsuranceServicesRevenue

120808000000

USD

CY2019

us-gaap

Insurance Services Revenue

InsuranceServicesRevenue

103141000000

USD

CY2021

us-gaap

Net Investment Income

NetInvestmentIncome

1378000000

USD

CY2020

us-gaap

Net Investment Income

NetInvestmentIncome

877000000

USD

CY2019

us-gaap

Net Investment Income

NetInvestmentIncome

1005000000

USD

CY2021

antm

Net Gains Losses On Financial Instruments

NetGainsLossesOnFinancialInstruments

318000000

USD

CY2020

antm

Net Gains Losses On Financial Instruments

NetGainsLossesOnFinancialInstruments

182000000

USD

CY2019

antm

Net Gains Losses On Financial Instruments

NetGainsLossesOnFinancialInstruments

67000000

USD

CY2021

us-gaap

Revenues

138639000000

USD

CY2020

us-gaap

Revenues

121867000000

USD

CY2019

us-gaap

Revenues

104213000000

USD

CY2021

us-gaap

Operating Income Loss

OperatingIncomeLoss

7489000000

USD

CY2020

us-gaap

Operating Income Loss

OperatingIncomeLoss

6360000000

USD

CY2019

us-gaap

Operating Income Loss

OperatingIncomeLoss

5999000000

USD

CY2021

us-gaap

Net Investment Income

NetInvestmentIncome

1378000000

USD

CY2020

us-gaap

Net Investment Income

NetInvestmentIncome

877000000

USD

CY2019

us-gaap

Net Investment Income

NetInvestmentIncome

1005000000

USD

CY2021

antm

Net Gains Losses On Financial Instruments

NetGainsLossesOnFinancialInstruments

318000000

USD

CY2020

us-gaap

Interest Expense

InterestExpense

784000000

USD

CY2019

us-gaap

Interest Expense

InterestExpense

746000000

USD

CY2019

antm

Net Gains Losses On Financial Instruments

NetGainsLossesOnFinancialInstruments

67000000

USD

CY2021

us-gaap

Interest Expense

InterestExpense

798000000

USD

CY2021

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

441000000

USD

CY2020

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

361000000

USD

CY2019

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

338000000

USD

CY2021

us-gaap

Gains Losses On Extinguishment Of Debt

GainsLossesOnExtinguishmentOfDebt

-21000000

USD

CY2020

us-gaap

Gains Losses On Extinguishment Of Debt

GainsLossesOnExtinguishmentOfDebt

-36000000

USD

CY2019

us-gaap

Gains Losses On Extinguishment Of Debt

GainsLossesOnExtinguishmentOfDebt

-2000000

USD

CY2021

us-gaap

Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments

IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

7925000000

USD

CY2020

us-gaap

Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments

IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

6238000000

USD

CY2019

us-gaap

Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments

IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

5985000000

USD

CY2021Q4

us-gaap

Statutory Accounting Practices Statutory Capital And Surplus Required

StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired

6962000000

USD

CY2020Q4

us-gaap

Statutory Accounting Practices Statutory Capital And Surplus Required

StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired

5800000000

USD

CY2021

us-gaap

Statutory Accounting Practices Dividends Paid With Approval Of Regulatory Agency

StatutoryAccountingPracticesDividendsPaidWithApprovalOfRegulatoryAgency

3134000000

USD

CY2021Q4

antm

Estimated Future Dividend Payments

EstimatedFutureDividendPayments

3000000000

USD

Name	View Source	Status
0001156039-22-000009-index-headers.html	Edgar Link	pending
0001156039-22-000009-index.html	Edgar Link	pending
0001156039-22-000009.txt	Edgar Link	pending
0001156039-22-000009-xbrl.zip	Edgar Link	pending
antm-20211231.htm	Edgar Link	pending
antm-20211231.xsd	Edgar Link	pending
antm-20211231_cal.xml	Edgar Link	unprocessable
antm-20211231_def.xml	Edgar Link	unprocessable
antm-20211231_g1.jpg	Edgar Link	pending
antm-20211231_htm.xml	Edgar Link	completed
antm-20211231_lab.xml	Edgar Link	unprocessable
antm-20211231_pre.xml	Edgar Link	unprocessable
exhibit1011primarybluecros.htm	Edgar Link	pending
exhibit1012primaryblueshie.htm	Edgar Link	pending
exhibit21-20211231for10xk.htm	Edgar Link	pending
exhibit23-20211231for10xk.htm	Edgar Link	pending
exhibit311-20211231for10xk.htm	Edgar Link	pending
exhibit312-20211231for10xk.htm	Edgar Link	pending
exhibit321-20211231for10xk.htm	Edgar Link	pending
exhibit322-20211231for10xk.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R105.htm	Edgar Link	pending
R106.htm	Edgar Link	pending
R107.htm	Edgar Link	pending
R108.htm	Edgar Link	pending
R109.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R110.htm	Edgar Link	pending
R111.htm	Edgar Link	pending
R112.htm	Edgar Link	pending
R113.htm	Edgar Link	pending
R114.htm	Edgar Link	pending
R115.htm	Edgar Link	pending
R116.htm	Edgar Link	pending
R117.htm	Edgar Link	pending
R118.htm	Edgar Link	pending
R119.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R120.htm	Edgar Link	pending
R121.htm	Edgar Link	pending
R122.htm	Edgar Link	pending
R123.htm	Edgar Link	pending
R124.htm	Edgar Link	pending
R125.htm	Edgar Link	pending
R126.htm	Edgar Link	pending
R127.htm	Edgar Link	pending
R128.htm	Edgar Link	pending
R129.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R130.htm	Edgar Link	pending
R131.htm	Edgar Link	pending
R132.htm	Edgar Link	pending
R133.htm	Edgar Link	pending
R134.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ELV
Elevance Health, Inc. Stock $elv

2021 Q4 Form 10-K Financial Statement

#000115603922000009 Filed on February 16, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELV Elevance Health, Inc. Stock $elv

2021 Q4 Form 10-K Financial Statement

#000115603922000009 Filed on February 16, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELV
Elevance Health, Inc. Stock $elv